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Abstract 
 
Membrane penetration represents a critical step during virus infection. As 
nonenveloped viruses lack a surrounding lipid bilayer, they are unable to penetrate host 
membranes by a membrane fusion mechanism. Consequently, nonenveloped viruses 
must devise alternative strategies to enter the host cell. In the case of polyomavirus 
SV40 and human papillomavirus (HPV), these two nonenveloped DNA tumor viruses 
must hijack selective host factors in order to promote their membrane penetration.  
Upon endocytosis, SV40 traffics through the endosomal pathway to reach the 
endoplasmic reticulum (ER). Here the virion is inserted into the ER membrane and is 
extracted into the cytosol by the cytosolic extraction machinery composed of the Hsc70, 
SGTA, and Hsp105 chaperones. From the cytosol, the virus is transported into the 
nucleus to cause infection. My thesis work unambiguously identified Hsc70 as a critical 
component of the cytosolic extraction machinery that ejects SV40 from the ER into the 
cytosol, clarified the structure-function relationship of SGTA during this process, and 
unveiled SGTA’s ability to negatively regulate Hsc70’s action during this the ER-to-
cytosol membrane transport step. Moreover, my studies revealed that the Bag2 
nucleotide exchange factor (NEF) is a new component of the cytosolic extraction 
machinery. In this context, Bag2 stimulates SV40 release from Hsc70, promoting 
successful arrival of SV40 to the cytosol, leading to infection. Collectively, my findings 
identify a novel component of a cytosolic extraction machinery essential during 
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membrane penetration of a nonenveloped virus, and provide further mechanistic 
insights into this process. 
Similar to SV40, HPV membrane penetration requires host factors that are poorly 
characterized. After initial entry, HPV reaches the endosome, where the viral L2 minor 
capsid protein is inserted into the endosomal membrane. Membrane insertion of L2 is a 
decisive event because this step recruits the cytosolic sorting retromer complex to 
endosome-localized HPV, which in turn directs the virus to the Golgi apparatus. From 
this compartment, the virus enters the nucleus during mitosis where viral DNA is 
replicated. Through classic biochemical analyses, we recently reported that the 
transmembrane protease g-secretase acts as a novel chaperone that binds to and 
inserts L2 into the endosomal membrane, an essential HPV infection step. In this thesis, 
we now identify the g-secretase-binding partner d-catenin/p120 as a new host factor that 
interacts with L2 and promotes HPV infection. Our analysis further suggests a model in 
which p120 engages HPV early in infection, delivering the virus to g-secretase so that 
HPV can properly insert into the endosome membrane. In sum, my results provide 
fundamental insights into the infectious entry pathway of the nonenveloped SV40 and 
HPV by illuminating their membrane penetration mechanism.
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Chapter 1: Introduction 
Viruses must hijack cellular machineries in order to enter and infect host cells. 
Because the host’s cell surface and internal organelles are surrounded by membranes 
composed of a lipid bilayer, viral entry requires penetration of at least one of these 
cellular membrane barriers. In the case of an enveloped virus ensheathed by a lipid 
bilayer, membrane penetration occurs when the viral membrane fuses with the host 
membrane. However, because a nonenveloped virus is not surrounded by a lipid 
bilayer, membrane penetration must occur by a fundamentally different mechanism.  
Indeed, nonenveloped viruses have developed unique strategies to penetrate 
host membranes, enabling them to deliver the viral nucleic acids to appropriate cellular 
destinations to cause infection. In general, this process requires trafficking along a 
productive infectious route to a specific sub-cellular location where host factors induce 
viral conformational changes. For example, endocytosis of the nonenveloped 
adenovirus targets the virus to the endosome, enabling the low pH in this compartment 
to trigger release of the viral lytic protein VI from the core viral particle (1). Protein VI in 
turn binds to and ruptures the endosomal membrane, allowing the virus to reach the 
cytosol. Similarly, for the nonenveloped poliovirus, after reaching the endosome from 
the cell surface, structural changes experienced by the viral particle in this organelle 
induce the viral proteins VP1 and VP4 to insert into the endosomal membrane, 
promoting release of the viral RNA into the cytosol (2). While these examples reveal a
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level of insight into membrane penetration of nonenveloped viruses, a more 
comprehensive and mechanistic understanding of this process remains largely 
undefined, especially in comparison to our understanding of enveloped virus membrane 
fusion.  
 
PyV and disease 
A central focus of my thesis project is to clarify membrane penetration of the small 
nonenveloped DNA tumor polyomavirus (PyV). The first two human PyVs, JC and BK 
PyV, were discovered in 1971 (3,4). Since then, an additional 11 human PyVs have 
been identified (5-7), including some more prominent viruses such as the Merkel cell 
PyV, the causative agent of an aggressive skin cancer called Merkel cell carcinoma (8). 
PyVs are highly prevalent in the human population, with some such as the BK PyV 
estimated to infect up to 90% of the human population (5, 9-11). Although PyV 
infections are generally benign in healthy immunocompetent individuals, they pose a 
significant threat to immunocompromised patients (11). For instance, BK PyV, the 
causative agent of PyV-associated nephropathy (10), becomes problematic in 
transplant patients. Because no therapies currently exist for PyV-associated 
nephropathy, treatment requires reducing immunosuppressants, which often leads to 
graft rejection. As another example, JC PyV is a neurotropic virus that causes 
progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the 
central nervous system (12). In immunocompromised patients such as those infected by 
human immunodeficiency virus and suffering acquired immune deficiency syndrome 
(HIV/AIDS), JC PyV-induced PML is rather common. Despite the fact that PyVs were 
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discovered 45 years ago, effective treatments are currently lacking. However, recent 
advances in PyV research have made therapeutic development a realistic possibility.  
 
SV40 structure and entry pathway 
SV40 is the archetype PyV, displaying both genetic and structural similarity to 
human PyVs. Accordingly, elucidating SV40 entry should illuminate the human PyV 
infection pathway. Structurally, SV40 contains a circular doubled-stranded DNA genome 
of approximately five kilobase-pairs that encodes seven genes: three structural genes 
called VP1, VP2, VP3, and four non-structural genes called VP4, large T antigen, small 
T antigen, and agno protein (5,7,11,13). As a nonenveloped virus, SV40 lacks a 
surrounding envelope and instead contains a protein capsid composed of 360 VP1 
copies arranged as 72 pentamers that are displayed on the viral surface (Figure 1-1A). 
The pentamers are stabilized by disulfide bonds, as well as by interactions between the 
VP1 C-terminus, which invades a neighboring pentamer (14,15). VP1 also associates 
with the underlying internal hydrophobic proteins VP2 and VP3, which along with VP1, 
bind to the genome (16). When fully assembled, SV40 is approximately 45–50 nm in 
diameter (7,11,14). 
To infect cells, SV40 first binds to the glycolipid receptor ganglioside GM1 on the 
cell surface (17-19), becomes internalized, and traffics to the early and late endosomes 
(Figure 1-1B, step 1; (20)). The virus then sorts to the endoplasmic reticulum (ER) using 
a lipid-directed mechanism (Figure 1-1B, step 2; (17, 21,22)), from where it ejects 
across the ER membrane to reach the cytosol (Figure 1-1B, step 3). Upon reaching the 
cytosol, SV40 mobilizes to the nucleus (Figure 1-1B, step 4), where ensuing 
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transcription and replication of the viral genome cause lytic infection or cellular 
transformation (23,24). Although SV40 ER-to-cytosol membrane penetration - a 
decisive infection step - is not entirely understood, key concepts and cellular 
components involved in this pathway are slowly being unraveled (25). The emerging 
principle posits that SV40 hijacks elements of a major protein quality control pathway 
called ER-associated degradation (ERAD) during its ER membrane penetration. In 
typical ERAD, misfolded ER proteins are ejected to the cytosol by transporting across 
the ER membrane via the so-called Hrd1-Sel1L membrane complex; upon reaching the 
cytosol, the misfolded proteins are polyubiquitinated and degraded by the proteasome 
machinery (26). 
 
 ER luminal events  
After reaching the ER from the cell surface, SV40 is thought to disguise as a 
“misfolded” substrate, co-opting components of the ERAD machinery in order to 
penetrate the ER membrane and reach the cytosol. To do so, SV40 first undergoes 
conformational changes that partially uncoat the virus. This conformational change 
generates a hydrophobic viral particle that binds to and inserts into the ER membrane, a 
step required for successful membrane transport. Multiple PDI family members impart 
structural alterations to SV40 in the ER, including PDI, ERp57, and ERdj5 (27-29); there 
is evidence that ERdj5 also executes an important role during BK PyV infection (29). In 
the case of the murine PyV, another PDI family member called ERp29 was found to 
locally unfold the VP1 C-terminal arm (30,31), a reaction that in conjunction with PDI 
and ERp57 (28,32) generates a hydrophobic virus by exposing the internal hydrophobic 
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proteins VP2 and VP3 (33,34). Of note, the PDI-ERp57-ERp29 triad has also been 
reported to act on JC PyV during infection (35). 
Uncoating of SV40 (and other PyVs) by PDI family members exposes the 
underlying hydrophobic proteins VP2 and VP3. While the newly-generated hydrophobic 
viral particle can bind to and integrate into the hydrophobic ER membrane, this virus is 
also prone to aggregation. To prevent aggregation, the BiP chaperone is recruited to the 
virus (36,37), similar to its role in preventing aggregation of a misfolded client during 
ERAD (38). BiP’s ability to engage SV40 (and other cellular substrates) is strictly 
dependent on its nucleotide-bound states (39). In the ADP-bound form, BiP has a high 
affinity for its substrate, while ATP-BiP displays a low substrate-binding affinity. J-
proteins activate BiP’s intrinsic ATPase activity, converting ATP-BiP to ADP-BiP. By 
contrast, nucleotide exchange factors (NEFs) release ADP from ADP-BiP, enabling ATP 
to re-engage BiP and generate ATP-BiP. In this context, the ER-resident J-protein 
ERdj3 was found to promote SV40 ER membrane transport by stimulating SV40-BiP 
interaction (37), presumably after hydrophobic proteins VP2 and VP3 are exposed. 
When the SV40-BiP complex is proximal to the luminal surface of the ER membrane, 
the virus must be released from BiP to initiate ER membrane penetration and transport. 
Of the two established ER luminal NEFs, only glucose-regulated protein 170 kDa 
(Grp170), but not Sil1, promotes SV40 release from BiP in order to prime the virus for 
membrane penetration (40). Grp170 was also shown to bind directly to the Hrd1 adapter 
Sel1L (41). This positions Grp170 next to the ER membrane, suggesting that SV40 
release from BiP occurs proximal to the membrane. Such a scenario raises the 
possibility that release of the virus from BiP is coupled to membrane transport. 
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Interestingly, only Sel1L (27) but not Hrd1 (36) plays a role in SV40 and JC PyV 
infection (35). Why this is the case is unclear, but there is the possibility that Sel1L 
might operate independent of Hrd1 in some instances. For instance, there may exist a 
pool of Sel1L that does not bind to Hrd1. Instead, this Sel1L pool might recruit 
previously uncharacterized ER (or possibly cytosolic) proteins that promote PyV 
infection.  
While not identical for all PyV family members, a coherent theme has come into 
focus for ER luminal events initiating the virus membrane transport process. 
Specifically, upon reaching the ER from the plasma membrane, the virus initially 
undergoes conformational changes induced by ERAD factors such as the PDI family 
members - these reactions expose the inner hydrophobic VP2 and VP3 proteins and 
generate a hydrophobic viral particle. The hydrophobic virus is prevented from 
aggregation by the recruitment of ERAD molecular chaperones such as BiP. In the final 
phase, the hydrophobic virus disengages from the molecular chaperone, binds to and 
inserts into the ER membrane, and is now primed for penetration across the lipid 
bilayer.  
ER membrane events  
When the hydrophobic SV40 particle inserts into the ER membrane, the N-terminal 
region of the exposed VP2 protein binds to an ER membrane protein called B-cell 
receptor-associated protein 31 (BAP31) (36), which is thought to stabilize the 
membrane-embedded virus. Additional ER membrane components such as the Derlins 
have also been reported to mediate ER-to-cytosol transport of SV40 (27), as well as the 
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murine PyV (42), and BK PyV (43). However, the precise molecular contribution of 
Derlins to the membrane penetration event is unclear. 
In an unbiased RNA interference (RNAi) screen, three ER transmembrane J 
proteins (B12, B14, and C18) were found to be essential in promoting SV40 and BK 
PyV infection (37). Of these J proteins, B12 and B14 have been previously implicated in 
ERAD (44-46). Not surprisingly, due to their localization to the ER membrane, B12, B14, 
and C18 regulate the decisive virus ER-to-cytosol membrane transport step (37,47,48). 
Because these J proteins display their catalytic J-domain towards the cytosol, part of 
their mechanism of action likely involves the recruitment of cytosolic Hsc70 and 
associated co-chaperones used to extract the virus into the cytosol. Interestingly, using 
a knockdown-rescue approach, all three J proteins were shown to exert non-redundant 
roles during SV40 ER membrane penetration (48). These results suggest that each J 
protein imparts a unique function within the viral membrane transport pathway. One 
possibility is that an individual J protein binds to a distinct set of luminal, membrane, or 
cytosolic partners that are all necessary to support the membrane transport process. 
An outstanding question is whether there are specific regions within the vast ER 
membrane, which is composed of a complicated network of sheets and tubules (49), 
that serve as selective membrane penetration sites for the virus. To address this 
question, we and others reported that many of the ER membrane proteins that promote 
SV40 ER membrane transport, including BAP31, B12, B14, and C18, reorganize into 
distinct subdomains within the ER membrane called foci during SV40 infection (36, 
47,48,50); SV40 itself also accumulates in these virus-induced foci (36,47,48,50). 
Importantly, the VP2/VP3-exposed, membrane penetration-competent form of SV40 is 
 8 
found predominantly in these punctate structures (48). These collective findings suggest 
that virus-triggered foci represent viral cytosol entry sites from the ER. Consistent with 
this idea, the rate of focus formation was found to temporally parallel SV40 cytosol 
arrival from the ER (47), SV40 mutants which cannot transfer across the ER membrane 
to reach the cytosol also fail to trigger focus formation (48), and impairing SV40 release 
into the cytosol traps SV40 in the foci, leading to expansion of the foci structures (50). 
While these are compelling data to support the notion that SV40 possesses a unique 
ability to construct specific penetration sites on the ER membrane, the precise 
molecular mechanism by which the viral particle stimulates focus formation remains 
unclear. For instance, assuming that individual components of the foci structures must 
reorganize laterally within the ER lipid bilayer to generate the focus structure, how does 
SV40 exploit cellular mechanical forces to accomplish this difficult feat? In this regard, 
the force generated by the cytosolic kinesin-1 motor was shown to promote SV40-
induced focus formation (51). Whether forces derived from additional ER luminal, 
membrane, or cytosolic factors are harnessed to drive focus formation are unknown. 
Clearly, clarifying the nature of the virus-induced foci, as well as elucidating their precise 
physiologic functions, deserve more attention. 
Cytosolic events 
Although SV40 is partially uncoated when it penetrates the ER membrane, the size 
of these viral particles remains relatively large, with reports ranging from approximately 
35 nm (36) up to 45 nm (29,52) in diameter. Thus it is unlikely that the membrane-
inserted SV40 passively slips through the ER lipid bilayer to reach the cytosol. Instead, 
we postulate that a cytosolic extraction machinery “pulls” the viral particle into the 
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cytosol. During ERAD, the p97 chaperone normally provides the primary driving force to 
extract a misfolded client from the ER into the cytosol (53). However, this cytosolic 
ATPase is not involved in SV40 infection (36). Motivated by this observation, we used a 
classical biochemical approach to identify the putative cytosolic extraction machinery, 
guided by the basic premise that the membrane-bound J proteins B12, B14, and C18 
would recruit such a machinery. These efforts pinpointed a cytosolic ternary protein 
complex composed of Hsc70, Hsp105, Bag2, and SGTA that we called the virus 
“extraction machinery” (47,50,54,55). Within this extraction machinery, Hsc70 is a well-
established chaperone that uses its ATPase activity to drive numerous protein folding, 
degradation, and quality control processes (56). Hsp105 is an atypical Hsc70 family 
member that also harbors a bonafide chaperone activity which can be used to promote 
protein disaggregation (56,57). Bag2 is NEF of Hsc70, while SGTA is a Hsc70 co-
chaperone that controls the action of Hsc70 (58-61). In addition to its role regulating 
Hsc70, SGTA also catalyzes an important step in the guided entry of tail-anchored 
proteins (GET) pathway, which inserts tail-anchored (TA) proteins from the cytosol into 
the ER membrane (62,63). It is worth noting that individual components of the Hsc70-
Hsp105-Bag2-SGTA complex executes a role during ERAD (64,65,66).  
At the on-set of my thesis project, Hsp105 and SGTA were shown to play pivotal 
roles in promoting ER-to-cytosol membrane penetration of SV40 (47,50). Specifically, 
Hsp105 is thought to disassemble SV40 as the virus is extracted from the ER into the 
cytosol, while SGTA guides the virus from the ER into the cytosol via a poorly 
characterized mechanism (47,50). However, the functions of Hsc70 and Bag2, as well 
as whether any individual components of this extraction machinery mutually regulate 
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each other’s function during the virus membrane penetration process, remained 
unknown. Chapter 2 and 3 of this thesis will demonstrate the key findings of my thesis 
work, firmly establishing critical roles of Hsc70 and Bag2 in driving ER-to-cytosol 
membrane penetration of SV40 (54,55). Additionally, my results reveal that Hsc70’s 
action during SV40 ER membrane transport is negatively impacted by SGTA (54). 
Finally, I also demonstrate that SGTA – via its N-terminal domain – exerts an 
unanticipated role post ER membrane penetration (54). By revealing the molecular 
basis by which SV40 accomplishes its ER-to-cytosol membrane penetration, this thesis 
thus clarifies a decisive step during infectious entry of a nonenveloped virus. We 
envision these insights may illuminate membrane penetration of other PyV family 
members and perhaps other nonenveloped viruses.  
  
HPV and disease 
In addition to PyV, the human papillomavirus (HPV) is another nonenveloped 
DNA tumor virus that causes morbidity and mortality. There are more than 200 types of 
HPVs, which are divided into 5 genera: alpha, beta, gamma, mu and nu (67). Of these 
viruses, only viruses belonging to the alpha genera infect cutaneous and mucosal 
epithelia (67). High risks HPVs, including HPV16 and HPV18, are not only responsible 
for almost all cases of cervical cancer, but also cause anogenital and oropharyngeal 
cancer (68). Although a highly effective HPV vaccine exists, vaccination cannot be used 
to treat pre-existing HPV infections. In addition, many people worldwide do not have 
access to HPV vaccines, further highlighting the need for insights into HPV entry which 
might provide new therapeutic strategies (69,70).    
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HPV structure and receptor-engagement  
Structurally, HPV is approximately 55 nm in diameter (71). The icosahedral viral 
capsid is composed of 72 pentamers of the L1 major capsid protein, which encase up to 
72 copies of the L2 minor capsid protein (72). Protected inside the viral capsid is the 
double-stranded DNA genome of approximately 8 kilobase-pairs (73). While the HPV 
genome varies between types, four genes are conserved among all HPVs: the viral 
capsid genes L1 and L2, and the replication genes E1 and E2 (67).   
 Productive HPV entry begins with damage to the outermost layer of tissue of the 
stratified epithelium, which provides the virus physical access to the basal tissue layer 
(74). Infection at this basal layer allows for long-term, persistent infection to occur 
(75,76). The viral lifecycle is highly dependent on cell differentiation, as receptor binding 
and viral entry does not occur at the squamous stratified epithelial, but instead occurs 
only at the basal epithelial cells (75). As cell differentiation occurs, viral genome 
replication and gene expression becomes detectable (77).  
HPV endocytosis is a slow and asynchronous process, with the half-time of 
uptake varying from 4 to 12 hours (71). Initial binding of the virus to the cell surface 
occurs quickly, suggesting that the rate-limiting step during entry occurs post-
attachment (78). To date, the HPV entry receptor remains unknown. Prior to engaging 
the unknown entry receptor, HPV L1 binds to the primary attachment receptor heparin 
sulfate proteoglycans on the cell surface or laminin 332 of the extracellular matrix (79-
82). A conformational change ensues that results in cleavage of L1 by kallikrein-8 
(KLK8) (83). Presence of extracellular cyclophilins on HSPGs allows for their direct 
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access to HPV, and induces conformational changes that exposes the N-terminus of L2 
(84,85). The L2 N-terminus is then cleaved by the transmembrane protein furin (81, 86, 
87). This cleavage promotes release of HPV from the attachment receptor, enabling the 
virus to be transferred to the postulated entry receptor (88, 89). There is evidence that 
receptor-dependent internalization mediated by the postulated entry receptor acts as a 
rate-limiting step during viral endocytosis (90).  
 
Endocytosis and transport to endosome 
Although HPV endocytosis is actin-dependent, the role of clathrin remains 
controversial, possibly due to studies using different pseudoviruses, cell lines, and 
means of disrupting clathrin function (71, 91). After endocytosis, HPV reaches the 
endosome. Here, virus disassembly is initiated when the low pH and the action of 
cyclophilins promote dissociation of the majority of L1 from the L2-DNA complex (92-
94). Importantly, L2 remains associated with the viral DNA, guiding transport of the viral 
DNA to the nucleus (95). In the endosome, HPV encounters the transmembrane 
protease g-secretase complex (96-99). Our lab recently revealed that g-secretase 
promotes insertion of L2 across the endosomal membrane (99), initiating virus 
membrane penetration essential during HPV infection (100). 
 
Targeting to the Golgi 
Insertion of L2 into the endosomal membrane is critical for HPV infection, 
because this step exposes the C-terminus of L2 to the cytosol (100). As the L2 C-
terminus harbors a retromer-binding motif, L2 membrane insertion can recruit the 
 13 
cytosolic retromer complex to the membrane-inserted virus (98, 99, 101-103). Because 
the retromer complex normally targets cargos from the endosome to the trans Golgi 
network (TGN) and Golgi, its recruitment to the virus sorts endosome-localized HPV to 
the Golgi (99, 101,102,104). 
 
Nuclear entry  
The L2-viral DNA complex remains in the Golgi until the host cell undergoes 
mitosis. Two critical events occur during mitosis essential for HPV infection: the Golgi 
membrane fragments and the nuclear envelope disassembles (105). Golgi membrane 
fragmentation generates Golgi-derived vesicles (GDVs) that harbor HPV, which can 
gain entry to the nucleus due to disassembly of the nuclear envelope (106). In this 
manner, HPV is deposited into the nucleus upon re-assembly of the nuclear envelope at 
the end of mitosis. Within the nucleus, HPV (harbored in the GDV) is physically tethered 
to mitotic chromosomes as a result of the exposed L2 C-terminus, which contains a 
DNA binding-site (107-109). Topologically, the L2-viral DNA complex can only be 
exposed to the nucleoplasm when it penetrates the limiting membrane of the GDV; how 
this is accomplished is not known. Regardless, transcription and replication of the viral 
genome is postulated to occur in or surrounding the promyelocytic leukemia protein 
(PML) nuclear bodies within the nucleus (95). 
 
p120 catenin in HPV infection  
In addition to elucidating ER membrane penetration of SV40, this thesis will also 
clarify the molecular basis by which HPV penetrates the endosomal membrane, a 
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critical step that properly directs the virus to the Golgi en route for successful infection. 
Although penetration of HPV into the endosomal membrane depends on g-secretase, 
how HPV is targeted to g-secretase in the endosome is unknown. My thesis work will 
clarify this targeting step. 
Using an unbiased immunoprecipitation (IP)-mass spectrometry approach, p120 
catenin (ctn) was implicated as a host factor that binds to HPV L2 during infection. p120 
is a member of the p120ctn family (110). Members of this family belong to the larger 
catenins family including alpha and beta catenin, as well as plakoglobin (111). Catenins 
are well-known for their role in cell-cell adhesion junctions, specifically through their 
interactions with cadherins (112,113), which are transmembrane receptors that form 
cell-cell adhesions via their extracellular domains (111). Importantly, p120 is known to 
interact with g-secretase (114). In fact, one critical function of p120 is to deliver a 
transmembrane protein to g-secretase, enabling g-secretase to proteolytically cleave the 
transmembrane protein in order to generate a cleaved product that elicits a defined 
cellular response (115). This thesis will assess the role of p120 during HPV infection, 
with the central objective of understanding how p120 might target HPV to g-secretase so 
that the virus can initiate membrane penetration – a critical infection step.  
In sum, the overarching theme of my thesis is to elucidate the mechanism of 
membrane penetration by the nonenveloped PyV and HPV. Chapters 2 and 3 will focus 
on the role of a specific host cytosolic extraction complex that completes the last phase 
of ER-to-cytosol membrane penetration of SV40, while chapter 4 will examine the action 
of p120 in targeting HPV to the g-secretase complex, which in turn promotes endosomal 
membrane penetration of the virus. I will then conclude this thesis with chapter 5, 
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bringing into perspective the contributions that I have made, as well as important 
questions that should be addressed in the future.  
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Introduction Figures 
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Figure 1-1. Simian virus 40 (SV40) structure and entry pathway. 
  
(A) SV40 consists of 360 VP1 copies arranged as 72 pentamers, which are localized on 
the viral surface. The pentamers are stabilized by disulfide bonds, as well as by 
interactions between the VP1 carboxy-terminus, which invades a neighboring pentamer 
(black curved lines). VP1 also binds to the underlying internal hydrophobic proteins VP2 
and VP3.  
(B) To infect cells, SV40 interacts with the glycolipid receptor ganglioside GM1 on the 
plasma membrane, internalizes, and traffics to the endolysosomes (step 1). The virus 
then targets to the endoplasmic reticulum (ER) using a lipid-sorting mechanism (step 2), 
from where it crosses the ER membrane to access the cytosol (step 3). Upon entering 
the cytosol, SV40 mobilizes into the nucleus (step 4), where ensuing transcription and 
replication of the viral genome causes lytic infection or cellular transformation. NPC: 
nuclear pore complex. 
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Figure 1-2. HPV entry pathway.  
 
To initiate infection, HPV binds HSPG on the plasma membrane. Conformational 
changes induced by KLK8, cyclophilins, and furin cleavage of L2 induce receptor 
binding, and promote endocytosis. Once endocytosed, the virus encounters g-secretase 
in the endosome, where L2 is inserted into the endosomal membrane. This insertion, 
and cytosolic exposure of L2 recruits the retromer complex, trafficking the endosomal-
L2 complex to the TGN. HPV resides in the TGN until mitosis, during which nuclear 
envelope breakdown facilitates HPV entry in to the nucleus where viral genome 
replication occurs.  
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Chapter 2: SGTA-Dependent Regulation of Hsc70 Promotes Cytosol Entry of 
Simian Virus 40 from the Endoplasmic Reticulum 
INTRODUCTION 
The molecular basis by which nonenveloped viruses penetrate biological 
membranes to gain entry into the host cytosol and cause infection remains mysterious 
(1). For enveloped viruses, fusion between the viral and a host membrane enables the 
core viral particle to reach the cytosol (2). However, since nonenveloped viruses lack a 
surrounding lipid bilayer, their membrane transport mechanisms are likely distinct from 
those of enveloped viruses. Although the precise molecular mechanism remains 
unclear, a general principle describing nonenveloped membrane translocation has 
nonetheless emerged. Upon trafficking to the site of membrane penetration, host cues, 
including cellular proteases, chaperones, reductases, and low pH, act on the viral 
particle to impart conformational changes. As a consequence, the conformationally 
altered virus becomes hydrophobic, enabling it to engage and disrupt the limiting 
membrane. Alternatively, the structural change may release a lytic peptide previously 
hidden in the native virus, which in turn integrates into and impairs the integrity of the 
membrane. Regardless of the mechanism, these reactions prime the viral (or subviral) 
particle for transfer across the host membrane. An outstanding question is whether 
cytosolic components are recruited to “pull” the virus into the cytosol to complete the 
membrane penetration process. 
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In the case of the nonenveloped polyomavirus simian virus 40 (SV40), 
penetration across the endoplasmic reticulum (ER) membrane to reach the cytosol 
represents the decisive infection step. Structurally, SV40 is composed of 72 pentamers 
of the coat protein VP1, with each pentamer harboring either the underlying internal 
hydrophobic protein VP2 or VP3 (3-6). These pentamers in turn encapsulate the viral 
DNA genome. VP1 C-terminal arms emanating from a pentamer invade adjacent 
pentamers and stabilize the overall viral architecture through a network of disulfide 
bonds and noncovalent interactions (3,4). To infect cells, SV40 binds to the ganglioside 
GM1 receptor on the host plasma membrane (7-10). After receptor-mediated 
endocytosis, the virus traffics to the endolysosomes (11,12) before being sorted to the 
ER (11-13). Here, SV40 penetrates the ER membrane to gain entry into the cytosol (14) 
and is further transported into the nucleus (15), where ensuing transcription and 
replication of the viral genome lead to lytic infection or cellular transformation. Although 
ER-to-cytosol membrane transport of SV40 remains enigmatic, aspects of this step are 
slowly being revealed. 
In the ER, redox enzymes reduce and isomerize the SV40 disulfide bonds (16-
18), while molecular chaperones locally unfold the VP1 C-terminal arms (17,19,20) to 
expose the internal proteins VP2 and VP3 (21,22). These events generate a 
hydrophobic virus that integrates into the ER membrane. To clarify how membrane-
embedded SV40 is ejected into the cytosol, we previously identified a cytosolic 
chaperone complex comprised of Hsc70, Hsp105, and SGTA that is tethered to the ER 
membrane by association with the membrane J-protein B14 (23-35). A J-protein 
typically stimulates Hsc70 (and Hsp70) chaperones to capture a substrate (26). In the 
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context of the Hsc70-Hsp105-SGTA protein complex, our analyses further unveiled 
important roles of Hsp105 and SGTA in extracting SV40 from the ER and transporting 
the virus to the cytosol (24, 25). Although our previous results also suggested that 
Hsc70 may be involved in this step (24,25), direct evidence demonstrating Hsc70's 
participation in the viral extraction step is lacking. Moreover, how Hsc70 might act in 
concert with Hsp105 or SGTA is also unclear. 
Using cell-based approaches, our study demonstrates that Hsc70 executes a key 
role in promoting cytosol entry of SV40 from the ER in a step that is regulated by SGTA. 
While SGTA's ability to interact with Hsc70 via its central tetratricopeptide repeat (TPR) 
domain is important during SV40's ER-to-cytosol transport, SGTA's N-terminal domain, 
which normally mediates homodimerization and recruits various cellular adapters, is not 
essential in this step. Instead, this domain appears to play an unanticipated post-ER 
membrane transport role during viral infection. Our results thus further illuminate the 
mechanistic basis by which a nonenveloped virus penetrates a host membrane. 
MATERIALS AND METHODS 
Antibodies 
Monoclonal SV40 large T antigen, Hsp90, and Hsp105 antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal VP1 antibody was provided by 
Walter Scott (University of Miami). Anti S-tag and anti-PDI (RL90) antibodies were 
purchased from Abcam (Cambridge, MA). DNAJB14 and SGTA antibodies were 
purchased from Proteintech Group (Chicago, IL). Monoclonal BAP31 and Hsc70 
antibodies were purchased from Pierce (Rockford, IL), and anti-FLAG antibody was 
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purchased from Sigma (St. Louis, MO). Anti-UBL4A antibody was kindly provided by the 
Protein Folding Disease Initiative at the University of Michigan and was purchased from 
Proteintech Group (Chicago, IL). Hsp27 antibody was purchased from Stressgen (San 
Diego, CA). Actin antibody was purchased from Cell Signaling (Danvers, MA). 
Polyclonal CTA antibody was produced against denatured CTA purchased from EMD 
Biosciences (San Diego, CA). 
Reagents 
FLAG M2 antibody-conjugated agarose beads, Triton X-100, and N-ethylmaleimide 
(NEM) were purchased from Sigma-Aldrich (St. Louis, MO). S-protein-conjugated beads 
were purchased from EMD Millipore Chemicals (San Diego, CA). Digitonin was 
purchased from EMD Millipore Chemicals (San Diego, CA). Opti-MEM and 0.25% 
trypsin were purchased from Invitrogen (Carlsbad, CA). DTT, dithiobis succinimidyl 
propionate (DSP), and phenylmethylsulfonyl fluoride (PMSF) were purchased from 
Sigma. The mounting reagent was Life Technologies ProLong Diamond antifade 
mountant with DAPI (4′,6′-diamidino-2-phenylindole) from Thermo Fisher (Carlsbad, 
CA). 
Cells 
CV-1, COS-7, and HEK293T cells (ATCC) were cultured in complete Dulbecco's 
modified Eagle medium (cDMEM) containing 10% fetal bovine serum, 10 U/ml penicillin, 
and 10 μg/ml streptomycin from Gibco (Grand Island, NY). 
DNA plasmids and siRNA transfection 
The siRNAs used were as follows: Hsc70 siRNA 1 (j-017609-02; Dharmacon), Hsc70 
siRNA 2 (5′-GACCUUCACUACCUAUUCU-3′; Dharmacon), SGTA siRNA 1 (5′-
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CAGCCUACAGCAAACUCGGCAACUA-3′; Invitrogen), SGTA siRNA 2 (5′-
CCAACCUCAAGAUAGCGGAGCUGAA-3′; Invitrogen), and scrambled control (all-star 
negative; Qiagen). WT SGTA-Myc/FLAG-containing plasmid was purchased from 
Origene (Rockville, MD). The amino acid positions defining the boundaries of SGTA's 
N- and Hsc70-binding TPR domains were defined based on UniProt. The ΔN SGTA 
construct was generated by deleting residues 1 to 90, the D3 mutant was created by 
using point mutagenesis that targets L15, A35, and L39, and the K160E/R164E mutant 
was generated using point mutagenesis targeting residues K160 and R164, as reported 
previously (24). All SGTA mutants contain a pcDNA3.1(−) vector backbone and harbor 
a C-terminal Myc/FLAG tag. In addition, all siRNA and DNA transfections were 
incubated for a minimum of 24 h. 
Preparation of SV40 
WT SV40 was prepared as described previously (14) using an OptiPrep gradient 
system (Sigma). 
Semipermeabilized, ER-to-cytosol membrane transport assay 
This assay has been previously described by Inoue and Tsai (14). Briefly, SV40-
infected CV-1 cells were trypsinized, washed in phosphate-buffered saline (PBS), and 
pelleted. The cell pellet was semipermeabilized in 0.1% digitonin in a physiological 
buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, and PMSF). For infected COS-7 cells, 
0.025% digitonin was used. The cells were then centrifuged at 4°C at 16,000 × g to 
generate two fractions: a supernatant fraction that represents the cytosol fraction and a 
pellet fraction that represents the membrane fraction. Samples were subjected to either 
reducing (in the case of CV-1-infected cells) or nonreducing (in the case of COS-7-
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infected cells) SDS-PAGE. To isolate ER-localized SV40, the membrane fraction was 
further lysed in a physiological buffer containing 1% Triton X-100. The extracted 
material represents the ER-localized fraction. 
SV40 infection 
Monitoring of SV40 large T antigen expression in the host nucleus has been previously 
described by Ravindran et al. (25). All images provided were taken with an inverted 
epifluorescence microscope (Eclipse TE2000-E; Nikon, Melville, NY). A standard 40× 
lens objective was used, along with blue (DAPI), fluorescein isothiocyanate (green), and 
TRITC (tetramethyl rhodamine isothiocyanate; red) filter cubes. Images were analyzed 
using ImageJ software. Cell counting was done using ImageJ software (Plugin cell 
counter). In the SGTA knockdown-rescue experiments, only cells expressing the FLAG-
tagged protein were counted. 
ER-to-cytosol transport of cholera toxin 
ER-to-cytosol transport of cholera toxin was performed as previously described by 
Williams et al. (29), except that cells were transfected with 30 nM Hsc70 siRNA 1 or 
control siRNA. 
ER transmembrane protein BAP31 focus-tracking assay 
The ER transmembrane protein BAP31 focus-tracking assay was carried out as 
previously described by Ravindran et al. (25). Briefly, CV-1 cells were seeded on sterile 
glass coverslips and transfected with 30 nM control or Hsc70 siRNA (siRNA 1 or siRNA 
2). After 24 h of transfection, the cells were infected with SV40 (MOI of ∼4 to 5) for 16 h. 
The cells were washed in PBS, fixed in 1% paraformaldehyde (PFA) in PBS for 15 min 
at 25°C, and permeabilized with 0.2% Triton X-100 for 5 min at 25°C. After 
 37 
permeabilization, the cells were incubated with anti-BAP31 and anti-VP1 antibodies for 
1 h at 25°C. Following primary antibody incubation, the cells were washed in 5% milk (in 
PBS and 0.02% Tween 20) and then incubated with anti-mouse (Alexa Fluor 488) and 
anti-rat (rhodamine) secondary antibodies for 30 min in the dark at 25°C. After 
incubation, the cells were washed, and the coverslips were dried and mounted on 
slides. At least 100 cells were counted per biological replicate, and at least three 
biological replicates were performed. Merge (3× zoom) was done using PowerPoint 
software. 
Hsc70 immunoprecipitation 
In the case of SGTA knockdown, CV-1 cells were transfected with 20 nM SGTA siRNA 
or 20 nM scrambled siRNA using RNAiMAX for 24 h in 10-cm plates. The cells were 
then transfected with 3 μg of plasmid containing Hsc70-S for 32 h. In the case of SGTA 
overexpression, COS-7 cells were transfected with 8 μg of either WT SGTA-Myc/FLAG- 
or GFP-FLAG-containing plasmids in addition to 3 μg of Hsc70-S-containing plasmids 
for 32 h. After DNA transfection, the cells were infected with SV40 (MOI of ∼4 to 5) for 
16 h. The cells were then lysed in a lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 
and PMSF) containing 1% Triton X-100 at 4°C for 10 min. Cells were then centrifuged at 
16,000 × g at 4°C for 10 min. The resulting cell extract was incubated with S-protein-
conjugated beads for 2 h, washed with the lysis buffer, and boiled in 2× SDS sample 
buffer with 5% β-mercaptoethanol (BME). The samples were subjected to SDS-PAGE 
and immunoblotting. 
 38 
Coimmunoprecipitation 
HEK293T cells were seeded in 6-cm plates. After 24 h, the cells were transfected with 
plasmids encoding GFP-FLAG or with SGTA constructs containing Myc/FLAG tags 
using polyethyleneimine (PEI) and Opti-MEM. For SGTA dimerization analyses, cells 
were transfected with plasmids containing WT SGTA-S and the indicated SGTA-
Myc/FLAG or GFP-FLAG constructs. After 48 h, the cells were washed in PBS and 
lysed in 1% Deoxy Big CHAP (DBC) (G-Biosciences) in physiological buffer. Lysed cells 
were centrifuged at 16,000 × g for 10 min at 4°C. The resulting extract was incubated 
with FLAG M2 antibody-conjugated agarose beads and rotated at 4°C for 2 h. The 
precipitated material was washed in a buffer containing 0.01% Deoxy Big CHAP. Then 
5× SDS sample buffer with 5% BME was added to the beads, followed by boiling for 10 
min. Samples were subjected to SDS-PAGE and immunoblotting with the indicated 
antibodies. 
ΔN SGTA immunoprecipitation 
COS-7 cells were transfected with 12.5 nM SGTA siRNA 1 using RNAiMAX for 24 h. 
The cells were then transfected with 3 μg of GFP-FLAG or 4 μg of ΔN SGTA-Myc/FLAG 
using PEI and Opti-MEM for 24 h. Twenty-four h after DNA transfection, the cells were 
infected with SV40 (MOI of ∼3 to 4) for 16 h. At 16 hpi, the cells were cross-linked in 2 
mM DSP at 4°C for 30 min and quenched with 10 mM Tris at 4°C for 10 min. The cells 
were then lysed in 1% Deoxy Big CHAP in 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 20 
mM NEM, and PMSF at 4°C for 10 min. Lysed cells were centrifuged at 16,000 × g at 
4°C for 10 min. The supernatant was incubated with FLAG M2 antibody-conjugated 
agarose beads for 2 h and rotated at 4°C. After 2 h, the beads were washed with lysis 
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buffer and boiled in 5× SDS sample buffer with 5% BME for 10 min. The samples were 
subjected to SDS-PAGE and immunoblotting with the indicated antibodies. 
In vitro SV40-Hsc70 coimmunoprecipitation 
A 100-ng portion of SV40 was treated with 3 mM DTT and 10 mM EGTA in PBS for 45 
min at 37°C. After 45 min, 1 μg of GFP-FLAG or Hsc70-His was added to the virus, 
followed by incubation for 1 h at 25°C. VP1 antibody specific for the VP1 protein was 
added and rotated overnight at 4°C. After 18 h, protein A/G beads were added and 
rotated for 2 h at 4°C. After an additional 2 h, the beads were washed with 0.1% Deoxy 
Big Chap in physiological buffer. Next, 5× SDS sample buffer with 5% BME was added 
to the beads, followed by boiling for 10 min. The samples were subjected to SDS-PAGE 
and immunoblotting with the specified antibodies. 
Statistics 
 
Graphs represent the mean value of at least three independent experiments, and paired 
Student two-tailed t tests were used to determine the P values. 
 
RESULTS 
Hsc70 depletion impairs SV40 cytosol entry from the ER. 
Based on an RNA interference (RNAi) screen, DNAJ B14 (B14) was identified as 
an ER membrane J-protein that promotes ER-to-cytosol membrane penetration of SV40 
(23). Subsequent binding analyses identified a cytosolic complex composed of Hsc70, 
Hsp105, and SGTA that associates with B14 (24, 25). Importantly, loss- and gain-of-
function strategies revealed that Hsp105 and SGTA have a central function in extracting 
SV40 from the ER and transporting the virus to the cytosol (24, 25). Whether Hsc70 
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directly exerts a role in this process is unknown. To test this, we used a well-
characterized cell-based, semipermeabilized ER-to-cytosol transport assay. In this 
assay, simian CV-1 cells transfected with a control small interfering RNA (siRNA) 
(scrambled) or either of two specific siRNAs directed against Hsc70 (Hsc70 siRNA 1 or 
siRNA 2) were infected with SV40. CV-1 cells were used because they are a naturally 
permissive cell line commonly used to study SV40 infection. The cells were then 
harvested, treated with a low concentration of digitonin to permeabilize the plasma 
membrane without damaging internal membranes, and centrifuged. This procedure 
generates two fractions: (i) a supernatant fraction that contains cytosolic proteins and 
virus that reaches the cytosol (“cytosol”) and (ii) a pellet fraction that harbors 
membranes, including the ER, as well as virus associated with membranes 
(“membrane”). The integrity of the fractionation procedure can be monitored in the 
pelleting of the ER-resident protein disulfide isomerase (PDI) to the membrane fraction 
without significant release of this protein into the cytosolic fraction (Fig. 2-1A, compare 
the seventh to the third panel). In contrast, the majority of actin partitions to the cytosolic 
fraction with a lower level found in the membrane fraction that likely represents nuclear-
associated actin (Fig. 2-1A, compare the second to the sixth panel). Using this assay, 
we found that even a moderate knockdown of Hsc70 (Fig. 2-1A, fourth panel, compare 
lanes 2 and 3 to lane 1) is sufficient to potently reduce the SV40 VP1 level in the cytosol 
(Fig. 2-1A, first panel, compare lanes 2 and 3 to lane 1; the VP1 band intensity is 
quantified in Fig. 2-1B).  We intentionally kept the level of Hsc70 knockdown modest by 
using the lowest siRNA concentration for a minimal time to achieve protein knockdown 
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because a significant depletion of this chaperone is likely to compromise overall cellular 
integrity due to Hsc70's role as a general housekeeping protein. 
When ER-localized SV40 was isolated from the membrane fraction using a 
previously established biochemical fractionation protocol (14) (see Materials and 
Methods), we found that depleting Hsc70 did not decrease the VP1 level (Fig. 2-1A, 
eighth panel, compare lanes 2 and 3 to lane 1; the VP1 band intensity is quantified in 
Fig. 2-1C); in fact, Hsc70 siRNA 1 may have caused a slight increase in the ER-
localized SV40 level. Together, these findings suggest that Hsc70 promotes the release 
of SV40 into the cytosol from the ER. Because Hsc70 is an important housekeeping 
protein and its depletion may globally perturb cellular proteostasis, we assessed 
whether our results were specific to SV40 ER-to-cytosol transport or due to a general 
disruption of cellular processes. To this end, we used cholera toxin (CT), another toxic 
agent that also undergoes ER-to-cytosol membrane transport to cause disease (27-29), 
to evaluate whether the knockdown of Hsc70 affects its membrane transport process 
using the same semipermeabilized assay. To intoxicate cells, CT traffics from the cell 
surface to the ER, where its cholera toxin A (CTA) subunit is reduced to generate the 
catalytic CTA1 peptide which in turn transports across the ER membrane to reach the 
cytosol; in the cytosol, CTA1 induces cytotoxicity. When Hsc70 is depleted, neither the 
formation of CTA1 (Fig. 2-1D, fourth panel, compare lane 2 to lane 1) nor the arrival of 
CTA1 to the cytosol (Fig. 2-1D, first panel, compare lane 2 to lane 1) was affected. 
These results demonstrate that Hsc70 is unlikely to play a role in promoting either cell 
surface-to-ER or ER-to-cytosol transport of the toxin. Since Hsc70 knockdown does not 
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globally impair all ER-to-cytosol membrane transport processes, we conclude that 
Hsc70 selectively exerts a role during SV40's ER membrane penetration event. 
 
Knockdown of Hsc70 or SGTA enhances SV40-induced focus formation. 
We used an independent assay to further evaluate the idea that Hsc70 executes 
an important role in extracting SV40 from the ER and transporting the virus to the 
cytosol. When SV40 reaches the ER from the cell surface, it induces the reorganization 
of several ER membrane proteins (including BAP31) to distinct puncta called “foci” that 
act as cytosol entry sites for the virus (24, 25, 30); not surprisingly, SV40 itself is also 
concentrated in the foci. We reasoned that if Hsc70 extracts focus-localized SV40 from 
the ER and is necessary for cytosol arrival, depleting Hsc70 should trap the virus in the 
foci, thereby enhancing the focus structure. In fact, when Hsp105 of the Hsc70-Hsp105-
SGTA complex was depleted, the virus-induced focus structure increased (25). Indeed, 
we now find that when Hsc70 was knocked down, the number of cells containing at 
least one BAP31-positive focus increased (Fig. 2-2A, compare the top to the bottom 
row; quantified in Fig. 2-2B). These findings strengthen the notion that Hsc70 plays a 
key role in promoting SV40 release into the cytosol from the ER. 
We previously demonstrated that SGTA is part of the Hsc70-Hsp105-SGTA 
complex that facilitates SV40 ER-to-cytosol membrane transport (24). Not surprisingly, 
knocking down SGTA (using SGTA siRNA 1 and siRNA 2) also increased virus-induced 
focus formation (Fig. 2-2C, compare the top to the bottom row; quantified in Fig. 2-2D), 
similar to the effect of depleting Hsp105 (25) and Hsc70 (Fig. 2-2A and 2-2B). The 
similar phenotype (i.e., enhanced focus formation) observed when any single 
component of the Hsc70-Hsp105-SGTA complex is depleted suggests that these 
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individual components all contribute to the virus extraction event. We note that when a 
much higher SV40 concentration was used (multiplicity of infection [MOI] of ∼50), SGTA 
knockdown did not increase the formation of the virus-induced foci (24), likely because 
all the cells already displayed focus formation under the control condition. 
 
SGTA regulates SV40-Hsc70 interaction. 
As a cochaperone of Hsc70, SGTA has been previously shown to control 
Hsc70's intrinsic ATPase activity (31, 32). We therefore sought to determine whether 
SGTA within the Hsc70-Hsp105-SGTA complex might regulate Hsc70's function during 
the viral membrane extraction process. Binding analyses revealed that in SV40-infected 
CV-1 cells expressing S-tagged Hsc70 (Hsc70-S), affinity purification of Hsc70-S pulled 
down more SV40 in SGTA-depleted cells than in the control (Fig. 2-3A, first panel, 
compare lane 2 to lane 1; the VP1 band intensity is quantified in Fig. 2-3B). When the 
reverse experiment was conducted, we found that in comparison to cells expressing the 
control green fluorescent protein (GFP)-FLAG, overexpressing wild-type (WT) SGTA 
containing a Myc/FLAG tag at the C terminus (WT SGTA-Myc/FLAG) decreased the 
level of Hsc70-SV40 interaction (Fig. 2-3C, first panel, compare lane 2 to lane 1; 
quantified in Fig. 2-3C); this experiment was performed using (CV-1-derived) COS-7 
cells because they afford a higher transfection efficiency than CV-1 cells, which 
facilitated the experiment. When purified His-tagged Hsc70 (Hsc70-His) or GFP-FLAG 
(Fig 2-3E) was incubated with partially disassembled SV40 (due to dithiothreitol [DTT] 
and EGTA treatment), precipitation of SV40 pulled down Hsc70 but not GFP (Fig. 2-3F, 
first and second panels, compare lane 4 to lane 3). This finding demonstrates that 
Hsc70 interacts with SV40 directly. We note that the difference in SV40's ability to bind 
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to Hsc70 when SGTA's level is altered is likely not due to a simple competition between 
SGTA and Hsc70 for binding to the same SV40 substrate. This is because we 
previously used a purified system and found that purified WT SGTA containing 
copurified Hsc70 in fact binds more to SV40 than a SGTA mutant (see below) that does 
not copurify Hsc70 (24). Hence, our data demonstrate that SGTA regulates the SV40-
Hsc70 interaction (see Discussion). 
 
Structure-function analyses of SGTA. 
Because SGTA impacts the virus-Hsc70 interaction, we sought to determine 
whether SGTA's ability to associate with Hsc70 via SGTA's central TPR domain (Fig. 2-
4A) (32-34), as well as SGTA's N-terminal domain, which mediates homodimerization 
and the recruitment cellular adapters, including the Ubl4A-Tric35-Bag6 complex (33-36), 
is important during ER extraction and cytosol arrival of the virus. Since SGTA's C-
terminal domain is limited to substrate binding (31, 37, 38) and unlikely to control 
Hsc70's function, we did not characterize this domain in this study. Accordingly, in 
addition to WT SGTA-Myc/FLAG, we used a SGTA construct lacking its N-terminal 
domain (ΔN SGTA-Myc/FLAG, which lacks the first 90 amino acids of SGTA), a 
dimerization-defective mutant in which three residues (L15, A35, and L39) postulated to 
reside at the dimerization interface are simultaneously mutated to aspartic acid (D3 
SGTA-Myc/FLAG) and a TPR mutant that cannot bind to Hsc70 (K160E/R164E SGTA-
Myc/FLAG [24]). 
To test these constructs' behavior in our system, we first cotransfected WT SGTA 
containing an S-tag (WT SGTA-S) with either GFP-FLAG, WT SGTA-Myc/FLAG, ΔN 
SGTA-Myc/FLAG, or D3 SGTA-Myc/FLAG in cells. Immunoprecipitation using FLAG 
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antibody-conjugated agarose beads, followed by subjecting the precipitated material to 
SDS-PAGE and immunoblotting, revealed that precipitating WT SGTA-Myc/FLAG, but 
not GFP-FLAG, ΔN SGTA-Myc/FLAG, or D3 SGTA-Myc/FLAG, pulled down WT SGTA-
S (Fig. 2-4B, first panel, compare lane 2 to lanes 1, 3, and 4). These results confirm that 
SGTA's N-terminal domain is essential for dimerization (34). Moreover, by 
demonstrating that D3 SGTA does not dimerize, our data specifically pinpoint three 
critical residues lying at the SGTA dimerization interface (34) as essential for mediating 
this oligomerization process. 
When GFP-FLAG or WT SGTA-Myc/FLAG was individually transfected into the 
cells, precipitating WT SGTA-Myc/FLAG but not GFP-FLAG pulled down endogenous 
B14, Hsp105, Hsc70, and Ubl4A as expected (Fig. 2-4B, compare lane 6 to lane 5). In 
cells transfected with ΔN SGTA-Myc/FLAG, pulldown of this protein also coprecipitated 
endogenous B14, Hsp105, and Hsc70 but did not precipitate Ubl4A due to the absence 
of the N-terminal domain (Fig. 2-4B, lane 7). In addition, in cells expressing the 
dimerization-defective D3 SGTA-Myc/FLAG mutant, precipitating this mutant pulled 
down B14, Hsp105, and (with higher affinity) Hsc70 (Fig. 2-4B, lane 8). Why D3 SGTA 
binds to Hsc70 with greater efficiency is unclear, but the observation that D3 SGTA did 
not bind to Ubl4A suggests that SGTA dimerization may be required to engage Ubl4A. 
When a similar binding study was performed using K160E/R164E SGTA-
Myc/FLAG, precipitation analyses showed this Hsc70-binding-defective construct 
interacts with Ubl4A, but not B14, Hsp105, or Hsc70 (Fig. 2-4C, lane 3). K160E/R164E 
SGTA's inability to bind to Hsc70 confirms previous observations (32, 37, 39) and is 
likely the reason it cannot bind to B14, indicating the SGTA-B14 binding is likely indirect 
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and mediated by Hsc70. This SGTA mutant's failure to bind to Hsp105 could also be 
due to its inability to bind to Hsc70, again suggesting that Hsc70 mediates the SGTA-
Hsp105 interaction. 
 
SGTA's ability to bind to Hsc70 is crucial in SV40 ER-to-cytosol transport. 
We tested if SGTA's N terminus or its ability to dimerize is crucial to support 
SV40 cytosol entry from the ER using the cell-based semipermeabilized assay. We 
found that in SGTA-depleted cells, SV40's arrival to the cytosol was significantly 
impaired compared to that in control cells (Fig. 2-5A, first panel, compare lane 2 to lane 
1; the VP1 band intensity is quantified in Fig. 2-5C), as reported previously (24). Under 
the SGTA-knockdown condition, expressing a WT SGTA-Myc/FLAG construct that is 
resistant to the SGTA siRNA at a level similar to that of endogenous SGTA (Fig. 2-5A, 
second panel, lane 3) partially restored SV40's arrival to the cytosol (Fig. 2-5A, first 
panel, compare lane 3 to lane 2; quantified in Fig. 2-5C). Likewise, expressing either ΔN 
SGTA-Myc/FLAG or D3 SGTA-Myc/FLAG under the SGTA-depleted condition (Fig. 2-
5A, second panel, lanes 4 and 5) also partially restored the arrival of SV40 to the 
cytosol (Fig. 2-5A, first panel, compare lanes 4 and 5 to lane 3; quantified in Fig. 2-5C). 
These data suggest that SGTA's N-terminal domain and ability to dimerize are 
dispensable for supporting SV40's ER membrane transport. 
However, our results demonstrate that expressing K160E/R164E SGTA-
Myc/FLAG in cells depleted of SGTA (Fig. 2-5B, second panel, compare lane 3 to lane 
2) did not restore the block in SV40 cytosol entry due to depletion of SGTA (Fig. 2-5B, 
first panel, compare lane 3 to lane 2; quantified in Fig. 2-5C). This finding strengthens 
the idea that SGTA must engage Hsc70 in order to regulate the viral ER membrane 
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transport event, a view consistent with our data that SGTA regulates the Hsc70-SV40 
interaction (Fig. 2-3). 
 
SGTA's N-terminal domain and Hsc70-binding are essential to promote SV40 
infection. 
We used the same “knockdown-rescue” approach to evaluate structural features 
of SGTA that are necessary in supporting SV40 infection. Cells transfected with either 
scrambled or SGTA siRNA were cotransfected with the indicated FLAG construct, and 
virus infection was assessed by monitoring for the expression of viral large T antigen in 
the host nucleus. Only cells expressing the FLAG-containing protein were scored. Using 
this strategy, we found that expressing WT SGTA or D3 SGTA but not K160E/R164E or 
ΔN SGTA in SGTA-knockdown cells rescued the infection block caused by depleting 
SGTA (Fig. 2-6A). The finding that K160E/R164E SGTA cannot rescue infection under 
the SGTA knocked-down condition is in line with this construct's inability to restore 
cytosol entry of the virus from the ER in SGTA-depleted cells (Fig. 2-5B and 2-5C). 
However, the observation that ΔN SGTA fails to rescue infection despite the fact that it 
can restore cytosol entry of SV40 from the ER (Fig. 2-5A and 2-5C) raises the strong 
possibility that SGTA's N terminus exerts a post-ER membrane penetration role during 
entry. This SGTA mutant's inability to restore infection is not due to lack of virus binding, 
since our data revealed that ΔN SGTA coimmunoprecipitates with SV40 at 16 h 
postinfection (hpi; Fig. 2-6B, first panel, compare lane 2 to lane 1), when a significant 
portion of the virus has reached the cytosol from the ER. Moreover, during the 
postulated post-ER membrane penetration event, SGTA's N terminus appears to 
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function in a dimerization-independent fashion since the dimerization-defective D3 
SGTA is capable of restoring virus infection in SGTA-knockdown cells. 
 
DISCUSSION 
One of the least understood steps during membrane penetration of 
nonenveloped viruses is the events on the cytosolic side of the limiting membrane that 
impact the viral membrane translocation process. In the case of ER-to-cytosol 
membrane transport of SV40, the molecular basis by which host factors extract the virus 
from the ER and facilitate cytosol arrival is not completely understood. We previously 
identified a cytosolic protein complex composed of Hsc70, Hsp105, and SGTA that is 
tethered to the ER membrane through binding to the membrane J-protein B14 (24, 25). 
Although Hsp105 and SGTA within this complex was demonstrated to participate in 
extracting membrane-embedded SV40 from the ER and transporting the virus to the 
cytosol (24, 25), direct evidence demonstrating a function of Hsc70 in supporting viral 
extraction has yet to be firmly established. 
In this report, we used two independent approaches to determine the role of Hsc70 in 
stimulating cytosol release of SV40 from the ER (Fig. 2-6C). First, we used a cell-based, 
semipermeabilized transport assay and found that modestly knocking down Hsc70 is 
sufficient to robustly impair SV40 entry into the cytosol. This strongly supports the idea 
that Hsc70 exerts a role in the cytosol arrival of SV40. Second, we relied on an imaging 
strategy based on visualizing a suborganellar punctate structure called a focus that 
represents the virus cytosol entry site from the ER. In this case, we found that depleting 
Hsc70 enhances the formation of this structure, similar to the depletion of Hsp105 (25) 
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or SGTA (this study). Enhanced focus formation likely reflects the entrapment of SV40 
at the site of cytosol entry when the extraction machinery is impaired. This finding thus 
strengthens results using the semipermeabilized assay, furthering the hypothesis that 
Hsc70 directly participates in the extraction event. 
Our previous experiments hinted at a role for Hsc70 in mediating SV40 ER 
membrane penetration essential for virus infection. Specifically, we found that WT B14, 
but not an Hsc70-binding-defective B14 mutant, rescues SV40 infection in B14-depleted 
cells (24), suggesting that Hsc70 is involved in infectious SV40 entry. Likewise, for 
Hsp105, which can serve as a nucleotide exchange factor (NEF) against Hsc70 (40, 
41), our results indicated that WT Hsp105, but not a NEF-defective Hsp105, restores 
the block in SV40 infection in Hsp105-knockdown cells (25), again implicating a function 
of Hsc70 during SV40 entry. 
Another major point in this study is that SGTA controls SV40's ability to bind to 
Hsc70. Specifically, we found that depleting SGTA increased SV40 binding to Hsc70. 
Such an enhanced interaction might reflect preferential binding of SV40 to Hsc70 that is 
associated with the ER membrane. This would prevent efficient SV40 release into the 
cytosol and explain why SGTA depletion impairs SV40 extraction from the ER and 
cytosol arrival (24). In addition, we found that overexpressing SGTA decreased the 
virus-Hsc70 interaction. The SGTA depletion and overexpression data together suggest 
that SGTA favors the transition of Hsc70 from the high-affinity ADP-Hsc70 substrate-
binding state to the low-affinity ATP-Hsc70 state (Fig. 2-6C, zoomed panel). Although 
how SGTA precisely accomplishes this feat remains unclear, we envision two distinct 
possibilities. 
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In one scenario, SGTA disrupts Hsc70's intrinsic ATPase activity, which normally 
converts ATP-Hsc70 to ADP-Hsc70. This scenario would agree with a previous report 
demonstrating that SGTA inhibits Hsc70's ATPase activity (32) but differs from another 
study, where SGTA was shown to increase Hsc70's ATPase activity (31). The reason 
for these opposite observations is unclear, but it could be due to the use of different 
substrates and experimental conditions. In the second scenario, SGTA enhances the 
nucleotide exchange reaction to favor ATP-Hsc70 formation, perhaps by assisting the 
action of the Hsp105 NEF. Regardless of the mechanism, SGTA's ability to engage 
Hsc70 via its central TPR domain, but not SGTA's N-terminal domain, which is 
responsible for homodimerization and recruitment of cellular factors, is important in 
facilitating ER extraction and cytosol arrival of SV40. 
Finally, our data reveal a potential post-ER membrane penetration role of SGTA 
during SV40 infection. This is based on the observation that SGTA's N terminus, despite 
not being important in stimulating virus ER-to-cytosol membrane transport, is 
nonetheless critical for promoting infection. One possibility is that SGTA directly 
participates in delivering the virus from the cytosol into the nucleus. In fact, our 
laboratory has shown that SGTA binds to SV40 (24), and others have demonstrated 
that SGTA localizes to the nucleus (42,43). In this context, it should be noted that 
SGTA's N terminus does not contain a canonical nuclear localization sequence. Another 
possibility is that SGTA, via its N terminus, recruits a cellular component which in turn 
targets the virus into the nucleus. Clearly, future experiments are needed to clarify this 
intriguing observation. In summary, in the present study we furthered our understanding 
of how a nonenveloped virus penetrates a biological membrane during infection by 
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demonstrating that as part of the cytosolic Hsc70-Hsp105-SGTA complex, Hsc70 plays 
an essential role in ejecting the nonenveloped SV40 from the ER membrane and 
transporting the virus to the cytosol in a reaction controlled by SGTA. 
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Chapter 2 Figures:  
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FIG. 2-1 Hsc70 depletion impairs SV40 cytosol arrival from the ER.  
 
(A) CV-1 cells transfected with Hsc70 siRNA 1, Hsc70 siRNA 2, or scrambled siRNA 
were infected with purified SV40 for 16 h and subjected to the semipermeabilized, ER-
to-cytosol transport assay. Cytosol-, membrane-, and ER-localized fractions (see 
Materials and Methods) were analyzed by SDS-PAGE and immunoblotting.  
(B) The VP1 band intensity in the cytosol fraction in panel A was quantified by using 
ImageJ (National Institutes of Health) and plotted as a percentage of the VP1 band 
intensity in the scrambled siRNA-treated condition. The graph represents the means the 
SD from three biological replicates.  
(C) Same as in panel B, except quantification is of the VP1 band intensity in the ER-
localized fraction.  
(D) CV-1 cells transfected with Hsc70 siRNA 1 or scrambled siRNA were intoxicated 
with cholera toxin for 90 min. The cells were lysed in 0.1% digitonin and fractionated as 
in panel A. Both the cytosol and the membrane fractions were subjected to SDS-PAGE 
and immunoblotting. 
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FIG. 2-2 Knockdown of Hsc70 or SGTA enhances SV40-induced focus formation.  
 
(A) CV-1 cells were seeded on glass coverslips and simultaneously transfected with 
Hsc70 siRNA 1 (bottom row) or scrambled siRNA (top row). After 24 h of siRNA 
transfection, the cells were infected with SV40 (MOI of 4 to 5) for 16 h. At 16 hpi, the 
cells were fixed and stained for BAP31 (red) and VP1 (green) and imaged using 
fluorescence microscopy. Zoomed images (3X) of the white boxed area in the merged 
images are shown.  
(B) Data are plotted as the number of cells containing at least one BAP31 focus as a 
percentage of the scrambled siRNA-treated condition. The graph represents the means 
the SD from three biological replicates.  
(C) Same as in panel A, except that images derived from cells treated with SGTA siRNA 
2 are shown.  
(D) Same as in panel B, except the focus formation in panel C is quantified based on 
results derived from SGTA siRNA 1 and siRNA 2. 
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FIG. 2-3 SGTA regulates SV40-Hsc70 interaction.  
 
(A) CV-1 cells transfected with scrambled or SGTA siRNA 1 were cotransfected with 
Hsc70-S for 24 h, followed by 16 h of SV40 infection. Hsc70-S was affinity purified from 
the resulting whole-cell lysate, and the isolated sample was subjected to SDS-PAGE 
and immunoblotting.  
(B) Quantification of the VP1 band intensity in panel A as a percentage of the scrambled 
siRNA-treated cells. The graph represents the means the SD from three biological 
replicates. 
(C) Same as in panel A, except COS-7 cells transfected with Hsc70-S were 
cotransfected with GFP-FLAG or WT SGTA-Myc/FLAG. *, Degraded WT SGTA-
Myc/FLAG.  
(D) Quantification of the VP1 band intensity in panel C as a percentage of cells 
expressing GFP-FLAG. The graph represents the means the SD from three biological 
replicates.  
(E) Purified GFP-FLAG and Hsc70-His subjected to Coomassie blue staining.  
(F) Hsc70-His and GFP-FLAG were incubated with DTT-EGTA-treated SV40, followed 
by incubation with a VP1 specific antibody. The precipitated samples were subjected to 
SDS-PAGE and immunoblotting. 
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FIG. 2-4 Characterization of SGTA mutants.  
 
(A) Structures of WT and SGTA mutants used in this figure.  
(B) Cell lysates derived from HEK293T cells transfected with the indicated constructs 
were subjected to immunoprecipitation using FLAG antibody-conjugated agarose 
beads. The precipitated materials were subjected to SDS-PAGE and immunoblotting. 
(C) Same as in panel B, except the indicated constructs were used. The white 
intervening space indicates that the lanes were spliced from the same immunoblot. 
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FIG. 2-5 SGTA’s ability to bind to Hsc70 is important in promoting SV40 ER-to-cytosol 
transport.  
 
(A) COS-7 cells transfected with scrambled or SGTA siRNA 1 for 24 h were 
cotransfected with the indicated construct. The cells were then infected with SV40 for 16 
h, lysed, and fractionated as in Fig. 1A. Cytosol- and ER-localized fractions were 
subjected to nonreducing SDS-PAGE and immunoblotting.  
(B) Same as in panel A, except the indicated constructs were used.  
(C) Quantification of the VP1 band intensity in the cytosol fraction in panels A and B. 
The VP1 band intensity was quantified as a percentage of the scramble siRNA-treated 
condition. The data represent the means the SD of at least three biological replicates. 
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FIG. 2-6 SGTA’s N-terminal domain and Hsc70-binding are essential to promote SV40 
infection.  
 
(A) CV-1 cells transfected with GFP-FLAG, WT SGTA-Myc/FLAG, or mutant SGTA-
Myc/FLAG for 24 h were seeded on glass coverslips and transfected with scrambled or 
SGTA siRNA 1. Following 24 h of siRNA transfection, cells were infected with SV40 
(MOI of 1) for 20 h. Cells were then fixed, stained, and counted. Only cells expressing 
the FLAG protein were scored. At least 100 cells were counted per biological replicate. 
The graph represents means SD of at least three biological replicates.  
(B) COS-7 cells were transfected with SGTA siRNA 1 for 24 h and then transfected with 
GFP-FLAG or ΔN SGTA-Myc/FLAG for 24 h. Following 24 h of DNA transfection, cells 
were infected with SV40 (MOI of 3 to 4) for 16 h. At 16 hpi, cells were cross-linked with 
DSP, lysed in 1% DBC, and immunoprecipitated. Samples were subjected to SDS-
PAGE and immunoblotted with the indicated antibodies.  
(C) A model depicting a role of SGTA-dependent regulation of Hsc70 during ER 
extraction and cytosol arrival of the virus. The focus represents the postulated cytosol 
entry site for the virus. The inset shows two possible mechanisms by which SGTA 
controls SV40-Hsc70 interaction. See Discussion for more detail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
 
References:  
 
1. Tsai B. 2007. Penetration of nonenveloped viruses into the cytoplasm. Annu Rev 
Cell Dev Biol 23:23–43. doi:10.1146/annurev.cellbio.23.090506.123454.  
 
2. Poranen MM, Daugelavicius R, Bamford DH. 2002. Common principles in viral 
entry. Annu Rev Microbiol 56:521–538. 
doi:10.1146/annurev.micro.56.012302.160643.  
 
3. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC. 
1991. Structure of simian virus 40 at 3.8-Å resolution. Nature 354:278–284. 
doi:10.1038/354278a0.  
 
4. Stehle T, Yan Y, Benjamin TL, Harrison SC. 1994. Structure of murine 
polyomavirus complexed with an oligosaccharide receptor 
fragment. Nature 369:160–163. doi:10.1038/369160a0. 
 
5. Stehle T, Harrison SC. 1996. Crystal structures of murine polyomavirus in 
complex with straight-chain and branched-chain sialyloligosaccharide receptor 
fragments. Structure 4:183–194. doi:10.1016/S0969-2126(96)00021-4. 
 
6. Chen XS, Stehle T, Harrison SC. 1998. Interaction of polyomavirus internal 
protein VP2 with the major capsid protein VP1 and implications for participation 
of VP2 in viral entry. EMBO J 17:3233–3240. doi:10.1093/emboj/17.12.3233. 
 
7. Smith AE, Lilie H, Helenius A. 2003. Ganglioside-dependent cell attachment and 
endocytosis of murine polyomavirus-like particles. FEBS Lett 555:199–203. 
doi:10.1016/S0014-5793(03)01220-1. 
 
8. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapoport TA. 
2003. Gangliosides are receptors for murine polyoma virus and SV40. EMBO 
J 22:4346–4355. doi:10.1093/emboj/cdg439.  
 
9. Low JA, Magnuson B, Tsai B, Imperiale MJ. 2006. Identification of gangliosides 
GD1b and GT1b as receptors for BK virus. J Virol 80:1361–1366. 
doi:10.1128/JVI.80.3.1361-1366.2006.  
 
10. Campanero-Rhodes MA, Smith A, Chai W, Sonnino S, Mauri L, Childs RA, 
Zhang Y, Ewers H, Helenius A, Imberty A, Feizi T. 2007. N-glycolyl GM1 
ganglioside as a receptor for simian virus 40. J Virol 81:12846–12858. 
doi:10.1128/JVI.01311-07.  
 
11. Qian M, Cai D, Verhey KJ, Tsai B. 2009. A lipid receptor sorts polyomavirus from 
the endolysosome to the endoplasmic reticulum to cause infection. PLoS 
Pathog 5:e1000465. doi:10.1371/journal.ppat.1000465 
 66 
 
12. Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A. 
2011. Role of endosomes in simian virus 40 entry and infection. J Virol 85:4198–
4211. doi:10.1128/JVI.02179-10.  
 
13. Kartenbeck J, Stukenbrok H, Helenius A. 1989. Endocytosis of simian virus 40 
into the endoplasmic reticulum. J Cell Biol 109:2721–2729. 
doi:10.1083/jcb.109.6.2721.  
 
14. Inoue T, Tsai B. 2011. A large and intact viral particle penetrates the 
endoplasmic reticulum membrane to reach the cytosol. PLoS 
Pathog 7:e1002037. doi:10.1371/journal.ppat.1002037.  
 
15. Nakanishi A, Clever J, Yamada M, Li PP, Kasamatsu H. 1996. Association with 
capsid proteins promotes nuclear targeting of simian virus 40 DNA. Proc Natl 
Acad Sci U S A 93:96–100. doi:10.1073/pnas.93.1.96.  
 
16. Schelhaas M, Malmstrom J, Pelkmans L, Haugstetter J, Ellgaard L, Grunewald 
K, Helenius A. 2007.Simian virus 40 depends on ER protein folding and quality 
control factors for entry into host cells. Cell131:516–529. 
doi:10.1016/j.cell.2007.09.038.  
 
17. Walczak CP, Tsai B. 2011. A PDI family network acts distinctly and coordinately 
with ERp29 to facilitate polyomavirus infection. J Virol 85:2386–2396. 
doi:10.1128/JVI.01855-10.  
 
18. Inoue T, Dosey A, Herbstman JF, Ravindran MS, Skiniotis G, Tsai B. 
2015. ERdj5 reductase cooperates with protein disulfide isomerase to promote 
simian virus 40 endoplasmic reticulum membrane translocation. J Virol 89:8897–
8908. doi:10.1128/JVI.00941-15.  
 
19. Magnuson B, Rainey EK, Benjamin T, Baryshev M, Mkrtchian S, Tsai B. 
2005. ERp29 triggers a conformational change in polyomavirus to stimulate 
membrane binding. Mol Cell 20:289–300. doi:10.1016/j.molcel.2005.08.034.  
 
20. Gilbert J, Ou W, Silver J, Benjamin T. 2006. Downregulation of protein disulfide 
isomerase inhibits infection by the mouse polyomavirus. J Virol 80:10868–10870. 
doi:10.1128/JVI.01117-06.  
 
21. Daniels R, Rusan NM, Wadsworth P, Hebert DN. 2006. SV40 VP2 and VP3 
insertion into ER membranes is controlled by the capsid protein VP1: implications 
for DNA translocation out of the ER. Mol Cell 24:955–966. 
doi:10.1016/j.molcel.2006.11.001.  
 
 67 
22. Kuksin D, Norkin LC. 2012. Disassembly of simian virus 40 during passage 
through the endoplasmic reticulum and in the cytoplasm. J Virol 86:1555–1562. 
doi:10.1128/JVI.05753-11.  
 
23. Goodwin EC, Lipovsky A, Inoue T, Magaldi TG, Edwards AP, Van Goor KE, 
Paton AW, Paton JC, Atwood WJ, Tsai B, DiMaio D. 2011. BiP and multiple 
DNAJ molecular chaperones in the endoplasmic reticulum are required for 
efficient simian virus 40 infection. mBio 2:e00101–00111. 
doi:10.1128/mBio.00101-11.  
 
24. Walczak CP, Ravindran MS, Inoue T, Tsai B. 2014. A cytosolic chaperone 
complexes with dynamic membrane J-proteins and mobilizes a nonenveloped 
virus out of the endoplasmic reticulum. PLoS Pathog10:e1004007. 
doi:10.1371/journal.ppat.1004007.  
 
25. Ravindran MS, Bagchi P, Inoue T, Tsai B. 2015. A nonenveloped virus hijacks 
host disaggregation machinery to translocate across the endoplasmic reticulum 
membrane. PLoS Pathog 11:e1005086. doi:10.1371/journal.ppat.1005086.  
 
26. Kampinga HH, Craig EA. 2010. The HSP70 chaperone machinery: J proteins as 
drivers of functional specificity. Nat Rev Mol Cell Biol 11:579–592. 
doi:10.1038/nrm2941.  
 
27. Lencer WI, Tsai B. 2003. The intracellular voyage of cholera toxin: going 
retro. Trends Biochem Sci28:639–645. doi:10.1016/j.tibs.2003.10.002.  
 
28. Bernardi KM, Forster ML, Lencer WI, Tsai B. 2008. Derlin-1 facilitates the retro-
translocation of cholera toxin. Mol Biol Cell 19:877–884. doi:10.1091/mbc.E07-
08-0755.  
 
29. Williams JM, Inoue T, Chen G, Tsai B. 2015. The nucleotide exchange factors 
Grp170 and Sil1 induce cholera toxin release from BiP to enable 
retrotranslocation. Mol Biol Cell 26:2181–2189. doi:10.1091/mbc.E15-01-0014.  
 
30. Bagchi P, Walczak CP, Tsai B. 2015. The endoplasmic reticulum membrane J 
protein C18 executes a distinct role in promoting simian virus 40 membrane 
penetration. J Virol 89:4058–4068. doi:10.1128/JVI.03574-14.  
 
31. Tobaben S, Thakur P, Fernandez-Chacon R, Sudhof TC, Rettig J, Stahl B. 
2001. A trimeric protein complex functions as a synaptic chaperone 
machine. Neuron 31:987–999. doi:10.1016/S0896-6273(01)00427-5.  
 
32. Angeletti PC, Walker D, Panganiban AT. 2002. Small glutamine-rich protein/viral 
protein U-binding protein is a novel cochaperone that affects heat shock protein 
70 activity. Cell Stress Chaperones 7:258–268. doi:10.1379/1466-
1268(2002)007<0258:SGRPVP>2.0.CO;2.  
 68 
 
 
33. Chartron JW, Gonzalez GM, Clemons WM Jr. 2011. A structural model of the 
Sgt2 protein and its interactions with chaperones and the Get4/Get5 complex. J 
Biol Chem 286:34325–34334. doi:10.1074/jbc.M111.277798.  
 
34. Chartron JW, VanderVelde DG, Clemons WM Jr. 2012. Structures of the 
Sgt2/SGTA dimerization domain with the Get5/UBL4A UBL domain reveal an 
interaction that forms a conserved dynamic interface. Cell Rep 2:1620–1632. 
doi:10.1016/j.celrep.2012.10.010.  
 
35. Xu Y, Cai M, Yang Y, Huang L, Ye Y. 2012. SGTA recognizes a noncanonical 
ubiquitin-like domain in the Bag6-Ubl4A-Trc35 complex to promote endoplasmic 
reticulum-associated degradation. Cell Rep2:1633–1644 
doi:10.1016/j.celrep.2012.11.010.  
 
36. Darby JF, Krysztofinska EM, Simpson PJ, Simon AC, Leznicki P, Sriskandarajah 
N, Bishop DS, Hale LR, Alfano C, Conte MR, Martinez-Lumbreras S, Thapaliya 
A, High S, Isaacson RL. 2014. Solution structure of the SGTA dimerization 
domain and investigation of its interactions with the ubiquitin-like domains of 
BAG6 and UBL4A. PLoS One 9:e113281. doi:10.1371/journal.pone.0113281.  
 
37. Liou ST, Wang C. 2005. Small glutamine-rich tetratricopeptide repeat-containing 
protein is composed of three structural units with distinct functions. Arch Biochem 
Biophys 435:253–263. doi:10.1016/j.abb.2004.12.020.  
 
38. Roberts JD, Thapaliya A, Martinez-Lumbreras S, Krysztofinska EM, Isaacson RL. 
2015. Structural and functional insights into small, glutamine-rich, 
tetratricopeptide repeat protein alpha. Front Mol Biosci 2:71. 
doi:10.3389/fmolb.2015.00071.  
 
39. Wu SJ, Liu FH, Hu SM, Wang C. 2001. Different combinations of the heat-shock 
cognate protein 70 (hsc70) C-terminal functional groups are utilized to interact 
with distinct tetratricopeptide repeat-containing proteins. Biochem J 359:419–
426. doi:10.1042/bj3590419.  
 
40. Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU. 2006. Molecular 
chaperones of the Hsp110 family act as nucleotide exchange factors of 
Hsp70s. EMBO J 25:2519–2528. doi:10.1038/sj.emboj.7601138.  
 
41. Raviol H, Bukau B, Mayer MP. 2006. Human and yeast Hsp110 chaperones 
exhibit functional differences. FEBS Lett 580:168–174. 
doi:10.1016/j.febslet.2005.11.069. 
 
 69 
42. Cziepluch C, Kordes E, Poirey R, Grewenig A, Rommelaere J, Jauniaux JC. 
1998. Identification of a novel cellular TPR-containing protein, SGT, that interacts 
with the nonstructural protein NS1 of parvovirus H-1. J Virol 72:4149–4156.  
 
43. Yin H, Wang H, Zong H, Chen X, Wang Y, Yun X, Wu Y, Wang J, Gu J. 
2006. SGT, a Hsp90β binding partner, is accumulated in the nucleus during cell 
apoptosis. Biochem Biophys Res Commun 343:1153–1158. 
doi:10.1016/j.bbrc.2006.03.090.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
Chapter 3: Bag2 is a Component of the Cytosolic Extraction Machinery That 
Promotes Membrane Penetration of a Nonenveloped Virus 
 
 
Introduction 
 
Enveloped and nonenveloped viruses must devise strategies to penetrate a host 
membrane in order to cause infection. However, this process is likely intrinsically 
different between the two. For an enveloped virus, encasement in a lipid bilayer allows 
membrane fusion between viral and host membranes (1). In contrast, a nonenveloped 
virus, which lacks a surrounding lipid bilayer, must mount an alternative strategy for 
membrane penetration (1,2). Although this process is poorly understood, key strategies 
are becoming clearer. To prime the membrane transport process, a nonenveloped virus 
undergoes conformational changes induced by host factors (proteases, chaperones, 
and reductases) or the environment (low pH) at the membrane penetration site. These 
conformational changes can generate a hydrophobic viral particle that enables the virus 
to bind to and integrate into the limiting membrane. To complete membrane penetration, 
recent studies suggest a new strategy in which host factors are in fact exploited to “pull” 
a nonenveloped virus across the membrane (3,4), but this last step of nonenveloped 
virus membrane transport remains enigmatic.  
The nonenveloped polyomaviruses (PyVs) are highly prevalent and cause 
significant diseases in immunocompromised individuals (5,6). Due to its structural and  
genetic similarities to human PyV, studies on the simian PyV simian virus 40 (SV40) 
have provided significant insights into the cellular infection pathway of its human 
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counterparts. Structurally, SV40 is composed of 72 VP1pentamers that encase the viral 
DNA genome (7-9). To maintain stability, these pentamers are linked by disulfide bonds, 
as well as noncovalent interactions established when the VP1 C-terminal arm extends 
from one pentamer to an adjacent pentamer (7,8). Each VP1 pentamer harbors a 
hydrophobic VP2 or VP3 protein (7,8,10). SV40 infection is initiated when the virus 
binds to the ganglioside GM1 receptor at the plasma membrane (11-13). Upon 
endocytosis, the virus is delivered in a retrograde manner to endosomal compartments 
(14) and then to the endoplasmic reticulum (ER), where it penetrates the ER membrane 
in order to reach the cytosol (14-17). From the cytosol, the virus continues into the 
nucleus, where replication and transcription of the viral genome occur (18,19). In the 
ER, SV40 and other PyV family members experience conformational changes resulting 
from interactions with ER-resident chaperones that unfold the VP1 capsid and redox 
enzymes that reduce and isomerize the capsid disulfide bonds (20-24). These events 
render the virus hydrophobic by exposing underlying VP2 and VP3, allowing insertion of 
the virus into the ER membrane (25-27). Our laboratory previously identified the fact 
that ER membrane J proteins (B12, B14, and C18) act as docking sites to recruit a 
cytosolic chaperone complex that functions to extract SV40 from the ER into the cytosol 
(3, 4, 28). To date, the established components of this protein complex are Hsc70, 
SGTA, and Hsp105 (3, 4, 28). 
In one model describing the extraction process, Hsc70 binds to the membrane-
embedded SV40 when the ER membrane J proteins convert ATP-Hsc70 to ADP-Hsc70, 
which displays a high substrate-binding affinity. Once ADP-Hsc70 has reverted to ATP-
Hsc70 via the action of a nucleotide exchange factor (NEF), ATP-Hsc70 releases SV40 
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due to its low affinity for the substrate. Iterative cycles of binding to and release from 
Hsc70 eject the virus into the cytosol. In the context of this reaction, SGTA regulates 
Hsc70's ability to engage SV40 (28) and binds directly to SV40 (3), while Hsp105 
promotes SV40 disassembly, which likely facilitates the virus extraction process (4). 
Here, we report that the Bag2 NEF is a novel component of the cytosolic virus 
extraction machinery. Using both cell-based and in vitro assays performed under loss-
of-function conditions, our findings reveal that Bag2 is necessary for SV40 extraction 
from the ER into the cytosol because it acts as a NEF to trigger SV40 release from 
Hsc70, thereby enabling the virus to successfully reach the cytosol. These findings 
underscore the importance of host NEF activity during SV40 infection and reveal 
additional insights into the molecular mechanism of nonenveloped virus membrane 
penetration.  
 
Materials and Methods 
Antibodies 
Endogenous Bag2, PDI, anti-VP1, and anti-S antibodies were purchased from Abcam 
(Cambridge, MA). Hsc70 and BAP31 antibodies were purchased from Invitrogen 
(Carlsbad, CA). Actin antibody was purchased from Cell Signaling (Danvers, MA). Anti-
FLAG antibody was purchased from Sigma (St. Louis, MO). Monoclonal large T antigen 
Hsp90, and Hsp105 antibodies were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-B12 antibody was purchased from Proteintech Group (Chicago, IL). 
Reagents 
FLAG M2 antibody-conjugated beads, phenylmethylsulfonyl fluoride (PMSF), and Triton 
X-100 were purchased from Sigma-Aldrich (St. Louis, MO). S protein-conjugated beads 
 73 
and digitonin were purchased from EMD Millipore Chemicals (San Diego, CA). Opti-
MEM and 0.25% trypsin were purchased from Invitrogen (Carlsbad, CA). Prolong 
Diamond antifade mount with DAPI (4′,6-diamidino-2-phenylindole) mounting reagent 
was purchased from Thermo Fisher (Carlsbad, CA). Phosphate-buffered saline (PBS) 
(1×) was purchased from Gibco (Carlsbad, CA). Purified Hsc70 was purchased from 
StressMarq Biosciences (Victoria, British Columbia, Canada), and purified Bag2 was 
purchased from Fitzgerald Industries International (Acton, MA). Magnetic protein G-
conjugated Dynabeads were purchased from ThermoFisher (Carlsbad, CA). 
Cells 
CV-1, COS-7, and HEK 293T (ATCC) cells were cultured in complete Dulbecco's 
modified Eagle medium (cDMEM) supplemented with 10% fetal bovine serum (FBS), 10 
U/ml penicillin, and 10 μg/ml streptomycin from Gibco (Carlsbad, CA). 
DNA plasmid and siRNA transfection 
To generate a Bag2 expression construct, Bag2 was cloned from a 293T cDNA library 
and amplified by PCR. PCR fragments were then inserted into a pcDNA3.1(−) 
backbone. To generate an siRNA-resistant Bag2 construct, overlapping PCR was 
performed using the following primers: forward, 
CTCCGTGGAGACTATCAGGAATCCCCAGCAGCAAGAATCCCT, and reverse, 
ATTCCTGATAGTCTCCACGGAGACTTCAACGGTGAGAGTTCT. 
The amplified Bag2 fragment generates the following silent mutations (underlined): 
GTC TCC GTG GAGACT ATC AGG AAT. The I160A Bag2 mutant was generated 
using point mutagenesis at residue I160, as previously reported (32). All the Bag2 
constructs were inserted into the pcDNA3.1(−) backbone harboring a C-terminal FLAG 
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tag and subjected to DNA sequencing to confirm the sequence. The Bag2 siRNA 
sequence is 5′-GUUGGCUUUAGCGUUGAUCUUCGCCUG-3′ (Life Technologies), and 
the scrambled siRNA sequence is that of the “all-star negative” siRNA from Qiagen. All 
DNA and siRNA transfections were incubated for at least 24 h. 
Preparation of SV40 
Purified SV40 preparation using the OptiPrep gradient system (Sigma) has been 
described previously (33). 
Immunoprecipitation 
For affinity purification of S-tagged J proteins, HEK 293T cells were seeded in 6-cm 
plates. The cells were transfected or not with B12-S, B14-S, C18-S, or GFP-S for 24 h 
in polyethyleneimine (PEI) and Opti-MEM and lysed in 1% Triton X-100 in physiological 
buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, and phenylmethylsulfonyl fluoride 
[PMSF]) at 4°C. Postlysis, the cells were centrifuged at 16,000 rpm at 4°C for 10 min. 
The supernatant was collected and rotated at 4°C for 2 h with S protein-conjugated 
beads. The beads were washed three times and boiled in 5× SDS sample buffer before 
being subjected to SDS-PAGE and immunoblotting. For immunoprecipitation of 
endogenous B12, cells were lysed, and the resulting lysate was incubated with an 
antibody against B12 (or a nonspecific IgG control antibody). The lysates were then 
incubated with protein A agarose beads for 2 h. The precipitated materials were 
processed as described above. For immunoprecipitation of FLAG-tagged proteins, HEK 
293T cells were seeded in 6-cm plates and transfected with FLAG-tagged constructs in 
PEI and Opti-MEM for 24 h. The cells were lysed in 1% Triton X-100 in a physiological 
buffer at 4°C for 10 min and centrifuged at 16,000 rpm at 4°C for 10 min. The 
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supernatant was collected and rotated at 4°C for 2 h with M2 FLAG-conjugated beads. 
The precipitated materials were processed as described above. To examine the 
interaction between SV40 and Hsc70 under Bag2 knockdown conditions, COS-7 cells 
were seeded in 6-cm plates and treated with either 50 nM Bag2 siRNA or a scrambled 
siRNA. After 24 h, the cells were transfected with Hsc70-S for 24 h. The cells were then 
infected with SV40 (multiplicity of infection [MOI], ∼20 to 30) for 16 h before being lysed 
in 1% Triton X-100 in a physiological buffer at 4°C for 10 min. The cells were then 
centrifuged at 16,000 rpm for 10 min at 4°C. The supernatant was collected and rotated 
with S protein-conjugated beads for 2 h at 4°C. After 2 h, the beads were washed three 
times in lysis buffer. The beads were then treated with 5× SDS sample buffer and 
subjected to SDS-PAGE and immunoblotting. The graph in Fig. 3-5B represents three 
biological replicates, and the VP1 band was quantified using Image J software (National 
Institutes of Health) and normalized to affinity-purified Hsc70-S. 
SV40 infection 
CV-1 cells (3 × 105) were seeded and transfected with 50 nM Bag2 siRNA, 25 nM 
Hsp105 siRNA, or 50 nM scrambled siRNA (along with Opti-MEM and RNAiMax) onto 
glass coverslips in 6-well plates. The cells were incubated at 37°C for 48 h. For 
knockdown-rescue experiments, 1.5 × 105CV-1 cells were seeded and transfected using 
siRNA as described above. After 24 h of siRNA transfection, the cells were washed and 
transfected with the indicated FLAG-tagged constructs using Fugene and Opti-MEM, 
totaling 48 h of siRNA knockdown before infection. After 48 h, cells were infected with 
purified SV40 (MOI, ∼0.5 to 1.5) for 24 h. After 24 h, the cells were fixed in 1% 
paraformaldehyde (PFA) for 15 min, permeabilized in 0.2% Triton X-100 for 5 min, and 
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incubated with rabbit anti-FLAG and mouse anti-large T antigen antibodies for 1 h at 
25°C. The cells were then washed and incubated with anti-rabbit (Alexa Fluor 488) and 
anti-mouse (Alexa Fluor 594) antibodies in the dark at 25°C for 30 min. The cells were 
washed, dried, and mounted on slides using Prolong Diamond antifade mount with 
DAPI (Invitrogen). For evaluating SV40 infection in cells without DNA transfection, at 
least 1,000 cells were counted per condition. To assess SV40 infection in cells 
transfected with DNA, at least 100 cells were counted per condition. The graphs in Fig. 
3-2B, 3-2C and 3-6A represent the mean and standard deviation (SD) of at least 3 
biological replicates, with paired Student two-tailed t tests used to determine 
the P values. 
ER-to-cytosol transport assay 
The protocol for the ER-to-cytosol transport assay has been described previously (33). 
Briefly, CV-1 cells were seeded in 6-cm plates and transfected with 50 nM Bag2 siRNA, 
50 nM scrambled siRNA, or 25 nM Hsp105 siRNA for 24 h. After 24 h, the cells were 
infected with purified SV40 (MOI, ∼1 to 5) for 16 h. The cells were then treated with 
0.1% digitonin and centrifuged. The resulting supernatant fraction represented the 
cytosol fraction, while the pellet fraction represented the membrane fraction. When the 
membrane fraction was treated with 1% Triton X-100 and the extracted material was 
isolated, the fraction then contained ER-localized SV40. The VP1 band intensity was 
quantified using Image J software (National Institutes of Health) and normalized to 
Hsp90 loading control bands. 
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Focus formation assay 
The focus formation assay method has been described previously (3, 4, 30). Briefly, 
control or knocked-down cells were fixed 16 h postinfection (hpi) (MOI, ∼1 to 5) and 
stained with anti-rat BAP31 and anti-mouse VP1 antibodies for 1 h at 25°C. The cells 
were then washed and incubated with anti-mouse (Alexa Fluor 488) and anti-rat (Alexa 
Fluor 594) antibodies in the dark at 25°C for 30 min. For the knockdown-rescue focus 
formation assay, cells were transfected with siRNA as described above for 24 h, 
followed by DNA transfection of the indicated constructs for 24 h. The cells were fixed 
as described above and stained with anti-rat BAP31 and anti-rabbit FLAG and S 
antibodies. The cells were washed and incubated with anti-rat (Alexa Fluor 594) and 
anti-rabbit (Alexa Fluor 488) antibodies as described above. At least 100 cells were 
counted per condition, and 3 biological replicates were completed. The graphs in Fig. 3-
4C and 3-6B represent the means and standard deviations of at least 3 biological 
replicates, with paired Student two-tailed t tests used to determine P values. Using 
Image J (National Institutes of Health), the VP1 focus size was measured by 
transforming images to 8 bits, adjusting the threshold, and processing the images as 
binary with watershed. The focus size was then quantified in pixels squared. 
Bag2-dependent release of Hsc70 from SV40 
To isolate the Hsc70-SV40 complex, 1 μg of Hsc70, 250 ng of SV40, 1 mM MgCl2, 2 
mM ATP, and 1 mM DTT were incubated at 37°C in 0.1% Triton X-100 in PBS for 30 
min. Anti-VP1 antibody was added to the samples for 30 min at 25°C, followed by 
addition of magnetic protein G Dynabeads for 30 min at 25°C. The beads were then 
washed 2 times in PBS. The beads then harbored the Hsc70-SV40 complex. To induce 
release of Hsc70 from SV40, purified Bag2 was added to samples at the indicated 
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concentrations in the presence of 1 mM MgCl2, 1 mM KCl, and 2 mM ATP at 25°C for 
10 min. The beads were subsequently washed 2 times in PBS, boiled in 5× SDS 
running buffer for 10 min, and subjected to silver staining. 
 
Results 
Bag2 binds to ER membrane J proteins.  
Through a previously reported unbiased RNA interference (RNAi) screen, the ER 
membrane J proteins DNAJB12 (B12), DNAJB14 (B14), and DNAJC18 (C18) were 
found to be essential in promoting ER-to-cytosol membrane transport of SV40 (29). 
Using a biochemical protein-protein interaction strategy, the components of a cytosolic 
protein complex composed of Hsc70, SGTA, and Hsp105 were subsequently identified 
as binding partners of these three ER membrane J proteins that function to extract 
SV40 from the ER into the cytosol (3, 4, 28, 30). Whether additional cytosolic 
components play a role in this virus membrane transport process is unknown. 
In this context, we previously reported that when 3×FLAG-tagged B12 (3×FLAG-B12) 
stably expressed in a 293T cell line was immunoprecipitated and the precipitated 
material was subjected to mass spectrometry analysis, peptides corresponding to the 
cytosolic NEF Bag2 were identified (31) (Fig. 3-1A). Likewise, when 3×FLAG-C18 stably 
expressed in a 293T cell line was immunoprecipitated and the precipitated sample was 
analyzed by mass spectrometry, Bag2-derived peptides were also found (Fig. 3-1A). A 
similar analysis for 3×FLAG-B14 was not performed. These findings raise the possibility 
that Bag2 represents a novel binding partner of B12/C18. To test this, S-tagged B12 
(B12-S), B14 (B14-S), C18 (C18-S), and the control green fluorescent protein (GFP) 
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(GFP-S) were transiently transfected in 293T cells; the S-tagged protein was affinity 
purified (AP); and the AP sample was subjected to SDS-PAGE, followed by 
immunoblotting. We found that endogenous Bag2 coprecipitated with B12-S, B14-S, 
and C18-S but minimally with GFP-S (Fig. 3-1B, top row), suggesting that Bag2 
interacts with the ER membrane J proteins. Moreover, endogenous Bag2 can also bind 
to endogenous B12 (Fig. 3-1C, top row), indicating that this interaction is not an 
overexpression artifact. These results demonstrate that the ER membrane J proteins 
interact with Bag2. 
A J protein binds to and stimulates the ATPase activity of Hsc70 to generate 
ADP-Hsc70, while a NEF associates with Hsc70, converting ADP-Hsc70 to ATP-Hsc70. 
In this scenario, Hsc70 bridges the interaction between a J protein and a NEF. 
Accordingly, we asked if B12's interaction with Bag2 depends on Hsc70. To test this, we 
transfected 293T cells with either a FLAG-tagged B12 mutant that cannot bind to Hsc70 
(QPD B12-FLAG), wild-type B12 (WT B12-FLAG), or the control GFP (GFP-FLAG) 
construct. When the FLAG-tagged proteins were immunoprecipitated, endogenous 
Hsc70 was found in the WT B12-FLAG- but not the QPD B12-FLAG-precipitated 
sample (Fig. 3-1D, second row from top), indicating that WT B12, but not QPD B12, 
binds to Hsc70, as previously reported (31). Importantly, endogenous Bag2 was 
observed in the WT B12-FLAG-precipitated but minimally in the QPD B12-FLAG-
precipitated material (Fig. 3-1D, top row). These results suggest that B12's interaction 
with Bag2 depends on Hsc70. 
To corroborate these data, we performed the reverse experiment in which a 
Bag2 mutant previously shown to lack Hsc70 binding (I160A Bag2*) (32) (the asterisk in 
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the Bag2 constructs indicates that the backbone Bag2 sequence was modified, 
rendering it resistant to a Bag2-specific small interfering RNA [siRNA] [see Materials 
and Methods]) was tested for its ability to associate with B12. Indeed, endogenous B12 
and Hsc70 were pulled down when transfected FLAG-tagged WT Bag2 (WT Bag2*-
FLAG), but not I160A Bag2 (I160A Bag2*-FLAG), was precipitated (Fig. 3-1E, top and 
second panels). Collectively, these findings demonstrate that the B12-Bag2 interaction 
is mediated by Hsc70. 
 
Bag2 promotes SV40 infection.  
As B12 and Hsc70 are both necessary host factors for SV40 entry, we asked if 
Bag2 plays a role in SV40 infection. Successful SV40 infection can be monitored by 
expression of the virus-encoded large T antigen in the host nucleus. Accordingly, simian 
CV-1 cells (used classically to study SV40 infection) were transfected with either the 
control siRNA (scrambled), an siRNA targeting Bag2, Hsp105 (a positive control), or 
both Bag2 and Hsp105 siRNAs. The levels of Bag2 and Hsp105 proteins under the 
knockdown conditions are shown in Fig. 3-2A. When these cells were incubated with 
SV40 and analyzed by immunofluorescence microscopy, we found that SV40 infection 
robustly decreased in Bag2-depleted cells (Fig. 3-2B), similar to the extent observed 
when Hsp105 was knocked down, as previously reported (4). Simultaneous depletion of 
Bag2 and Hsp105 potently impaired virus infection, although it did not appear to 
exacerbate the single-knockdown phenotype. This finding suggests that neither NEF is 
sufficient to support SV40 infection. 
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To ensure that the block in SV40 infection in Bag2 siRNA-treated cells is 
specifically a result of depleting Bag2 and is not due to unintended off-target effects, we 
performed a knockdown-rescue experiment. To this end, cells transfected with either 
scrambled or Bag2 siRNA were cotransfected with either GFP-FLAG, WT Bag2*-FLAG, 
or I160A Bag2*-FLAG. The cells were incubated with SV40, and large T antigen 
expression was assessed in FLAG-expressing cells. Using this approach, we found that 
expressing WT, but not I160A, Bag2 largely restored SV40 infection in Bag2-depleted 
cells (Fig. 3-2C), indicating that the decrease in SV40 infection resulting from the Bag2 
siRNA is due to the loss of Bag2. These data demonstrate that Bag2 promotes SV40 
infection, and this is dependent on Bag2's ability to interact with Hsc70. 
 
Bag2 is important for ER-to-cytosol transport of SV40.  
As Bag2 is recruited to the ER membrane J proteins via Hsc70 (Fig. 3-1), we 
envision that Bag 2 is strategically localized to promote cytosol entry of SV40 from the 
ER membrane. To test this, we employed a cell-based, semipermeabilization assay that 
detects SV40 arrival in the cytosol from the ER. This assay, developed in our laboratory, 
is routinely used to characterize ER-to-cytosol membrane transport of PyV family 
members (33). In the assay, cells are treated with the gentle detergent digitonin, which 
permeabilizes the plasma membrane while maintaining the membrane integrity of 
intracellular organelles. Centrifugation of the semipermeabilized cells generates two 
fractions, a supernatant fraction that contains cytosolic proteins and virus that 
successfully reached the cytosol from the ER (cytosol), and a pellet fraction that harbors 
membranes, including the ER and virus that is trapped in the ER (membrane). Using 
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this method, cytosolic Hsp90 largely partitioned to the cytosol fraction (Fig. 3-3A, 
compare 2nd row to 7th row), while ER-resident PDI remained in the membrane fraction 
(Fig 3-3A compare 8th row to 3rd row), verifying the integrity of the fractionation 
protocol. Importantly, under these conditions, we found that the level of SV40 VP1 in the 
cytosol decreased markedly when Bag2 was knocked down (Fig. 3-3A, top row; the 
VP1 band intensity in the cytosol fraction is quantified in panel B), similar to the effect 
observed when Hsp105 is depleted, as previously reported (4). Using a biochemical 
extraction approach designed to isolate ER-localized SV40 from the membrane fraction 
(see Materials and Methods), we found that knockdown of neither Bag2 nor Hsp105 
significantly affected the level of ER-localized SV40 (Fig. 3-3A, 9th row), indicating that 
these cytosolic factors do not facilitate ER arrival of the virus from the cell surface. 
Hence, Bag2 plays an important role in promoting cytosol entry of SV40 from the ER, 
consistent with its function in supporting SV40 infection (Fig. 3-2). 
 
Depletion of Bag2 traps SV40 in the ER-to-cytosol membrane penetration site.  
As an independent approach to evaluate whether Bag2 promotes extraction of 
SV40 from the ER into the cytosol, we used a microscopy-based strategy. We and 
others previously demonstrated that upon reaching the ER, SV40 reorganizes selective 
ER membrane proteins (including the membrane J proteins and the BAP31 ER 
membrane protein) to distinct punctate structures in the ER harboring the virus, called 
foci (3, 4, 17, 30). Our findings further suggest that these virus-induced foci act as 
cytosol entry sites (3, 4, 30). We therefore reasoned that if Bag2 extracts SV40 from the 
ER into the cytosol, depletion of Bag2 should trap the virus in the foci, consequently 
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augmenting this virus-containing structure. To test this, CV-1 cells transfected with 
either the scrambled or Bag2 siRNA were infected with SV40 and stained for SV40 VP1 
and BAP31. Indeed, we found that depletion of Bag2 increased the number of cells 
containing at least one BAP31+ focus (Fig. 3-4A, compare bottom and top rows); the 
relative size of VP1 harbored in the BAP31+ focus also increased when Bag2 was 
depleted(Fig. 3-4B). These findings are consistent with the idea that Bag2 plays an 
important role in extracting SV40 from the ER into the cytosol. 
We further asked whether reexpression of WT Bag2, I160A Bag2, or HspBP1, a 
cytosolic NEF previously shown to be dispensable during SV40 infection (4), in Bag2-
depleted cells affected focus formation. For this, CV-1 cells transfected with either the 
scrambled or Bag2 siRNA were cotransfected with GFP-FLAG, WT Bag2*-FLAG, I160A 
Bag2*-FLAG, or HspBP1-S. The cells were then infected with SV40 and stained for 
BAP31. Only cells expressing the FLAG-tagged (or S-tagged) protein were assessed. 
Again, we found that depleting Bag2 increased the number of cells containing at least 
one BAP31+ focus (the extent of focus formation is quantified in Fig. 3-4C; 
representative images are shown in panel D). Importantly, add-back of WT Bag2*-
FLAG, but not I160A Bag2*-FLAG or HspBP1-S, in the Bag2-depleted cells reduced the 
number of cells harboring at least one BAP31+ focus to control levels (the extent of 
focus formation is quantified in Fig. 3-4C; see representative images in Fig. 3-4D). 
These results indicate that restoring Bag2 expression in Bag2-depleted cells can 
promote cytosol entry of the virus from the ER, thereby decreasing the focus structures. 
Thus, our microscopy-based analyses are in agreement with data from the 
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semipermeabilization assay, strengthening the hypothesis that Bag2 plays a decisive 
role in extracting SV40 from the ER into the cytosol. 
 
Bag2 triggers release of SV40 from Hsc70.  
Our data indicate that Bag2 binds to B12 via Hsc70. Because Bag2 functions as 
a NEF to induce substrate release from Hsc70 (32, 34), we hypothesized that Bag2 
induces release of SV40 from Hsc70 to promote cytosol entry. To test this, we 
transfected (CV-1-derived) COS-7 cells expressing Hsc70-S with scrambled or Bag2 
siRNA and precipitated Hsc70-S. (COS-7 cells were used because they support higher 
transfection efficiency than CV-1 cells). Importantly, under the Bag2 knockdown 
condition, Hsc70-S precipitated significantly more VP1 than cells treated with scrambled 
siRNA (Fig. 3-5A, top row; the VP1 band intensity is quantified in panel B), indicating 
that SV40 is trapped on Hsc70 in the absence of Bag2. This result is consistent with the 
hypothesis that Bag2 stimulates SV40 release from Hsc70. 
To strengthen this finding, we reconstituted the virus release reaction using 
purified components, including Hsc70, SV40, and Bag2 (Fig. 3-5C). In the ER, SV40 
undergoes disulfide bond reduction, priming it for insertion into the ER membrane (22, 
23). The reductant dithiothreitol (DTT) was therefore added to purified SV40 to partially 
mimic this reduced viral conformation. The reduced SV40 was incubated with Hsc70, 
followed by pulldown of SV40 in order to isolate the SV40-Hsc70 complex. Importantly, 
when this complex was subsequently incubated with increasing concentrations of Bag2 
in the presence of ATP and the SV40 was reisolated, the level of bound Hsc70 
decreased compared to addition of a control buffer containing only ATP (Fig. 3-5D, top 
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row, compare lanes 2 and 3 to lane 1). These findings demonstrate that Bag2 can 
promote disengagement of SV40 from Hsc70 in vitro, in agreement with the premise 
that Bag2 induces the release of SV40 from Hsc70 in the intact cell. 
 
Bag2 and Hsp105 play overlapping roles.  
Our results show that depleting either Bag2 or Hsp105 inhibits SV40 infection 
(Fig. 3-2B). Because Hsp105 is also a NEF of Hsc70 (35-37), we asked if Bag2 and 
Hsp105 perform overlapping roles. To test this, we transfected cells with scrambled, 
Bag2, or Hsp105 siRNA and cotransfected the cells with either GFP-FLAG, WT Bag2*-
FLAG, or Hsp105*-FLAG (Hsp105*-FLAG is a construct that is resistant to the Hsp105 
siRNA). Only FLAG-expressing cells were assessed for large T antigen expression in 
order to evaluate SV40 infection. We found that add-back of Bag2 largely restored the 
decrease in SV40 infection in Bag2-depleted cells (Fig. 3-6A, compare columns 3 and 
1, and 2C), while add-back of Hsp105 rescued the block in SV40 infection in Hsp105-
depleted cells (Fgi. 3-6A, compare 6th and 1st columns from left), which is consistent 
with our previous report (4). Strikingly, expression of Hsp105 fully restored SV40 
infection in Bag2-depleted cells (Fig. 3-6A, compare 4th and 1st columns from left), and 
likewise, expression of Bag2 rescued SV40 infection in Hsp105-depleted cells (Fig. 3-
6A, compare 7th and 1st columns from left). These results indicate that Bag2 and 
Hsp105 display overlapping functions. 
As both Bag2 (this study) and Hsp105 (4) promote the arrival of SV40 in the 
cytosol from the ER, we assessed if Bag2 and Hsp105 play overlapping roles at this 
step. To this end, cells transfected with scrambled or Bag2 siRNA were cotransfected 
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with GFP-FLAG, WT Bag2*-FLAG, or Hsp105*-FLAG. The cells were then infected with 
SV40 and stained for BAP31 and VP1 to detect formation of virus-induced focus 
structures that represent the virus' cytosol entry sites (Fig. 3-4A). We found that the 
enhanced focus formation observed in Bag2-depleted cells could be decreased to 
control levels by add-back of either WT Bag2*-FLAG or Hsp105*-FLAG (the extent of 
focus formation is quantified in Fig. 3-6B, with representative images in panel C), 
suggesting that SV40 trapped in the focus structure due to the absence of Bag2 can be 
released into the cytosol (thereby decreasing the focus structure) when Bag2 or Hsp105 
is added back. These results corroborate the infection data, suggesting that the two 
cytosolic NEFs have overlapping functions. 
Although Bag2 and Hsp105 must bind to Hsc70 to induce substrate release, 
whether they engage the same Hsc70 complex is unknown. We postulate that if Bag2 
and Hsp105 in fact interact with the same Hsc70 complex, precipitation of Bag2 should 
correspondingly pull down Hsp105, and vice versa. To test this, Hsp105*-FLAG, WT 
Bag2*-FLAG, and the control GFP-FLAG were immunoprecipitated, and the precipitated 
material was subjected to immunoblotting. We found that precipitation of Hsp105*-FLAG 
(but not GFP-FLAG) pulled down endogenous (and transfected) Hsp105 and Hsc70, but 
not endogenous Bag2 (Fig. 3-6D, top three rows, lanes 2). Similarly, precipitation of WT 
Bag2*-FLAG coprecipitated endogenous (and transfected) Bag2 and Hsc70, but not 
endogenous Hsp105 (Fig. 3-6D, top three rows, lanes 3). These results suggest that 
Bag2 and Hsp105 may form separate Hsc70 complexes. 
 
Discussion 
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Host membrane penetration is essential for successful virus infection. For a 
nonenveloped virus, this process remains enigmatic. In the case of the nonenveloped 
PyV SV40, penetration of the virus across the ER membrane to reach the cytosol 
represents a decisive infection step. However, the molecular basis by which host factors 
are exploited to extract the virus from the ER into the cytosol has yet to be fully clarified. 
We previously demonstrated that Hsc70, SGTA, and Hsp105 form a cytosolic 
chaperone-cochaperone complex that promotes cytosol entry of the virus from the ER 
(3, 4, 28); whether Hsp70 or additional cytosolic components participate in this virus 
extraction process is unknown. Here, we pinpoint the cytosolic NEF Bag2 as a novel 
cellular component that promotes SV40 infection by supporting viral ER-to-cytosol 
membrane transport. Our results indicate that Bag2 associates with Hsc70 and ER 
membrane J proteins to generate a protein complex that is likely distinct from the 
Hsp105-Hsc70-J protein complex (Fig. 3-7). Importantly, during SV40 entry, Bag2 acts 
as a NEF to stimulate virus release from Hsc70 in order to support cytosol entry of the 
virus (Fig. 3-7, inset). 
Our previous mass spectrometry data raised the possibility that Bag2 interacts 
with the ER membrane J protein B12 (31); a similar mass spectrometry approach also 
suggested that C18 engages Bag2. By immunoprecipitation and affinity purification, we 
confirmed that Bag2 indeed binds to B12 and C18, as well as the J protein B14, 
demonstrating that Bag2 is a bona fide binding partner of the J proteins. Using 
established Hsc70 binding-defective mutants of either Bag2 or B12, our results further 
indicate that the Bag2-B12 interaction occurs via an Hsc70 intermediate, revealing that 
this interaction is coupled through the Hsc70 chaperone. 
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Through knockdown-rescue experiments, we found that Bag2 executes an 
important Hsc70-dependent function to promote SV40 infection. We then took 
advantage of two independent strategies—a semipermeabilized fractionation method 
and a microscopy-based focus-tracking assay—to demonstrate that Bag2 promotes 
virus extraction from the ER to the cytosol to support virus infection. Hence, by strategic 
positioning at the ER membrane (via engaging the Hsc70-J protein complex), Bag2 
triggers cytosol entry of SV40 from the ER. Whether Bag2 impacts ER-to-cytosol 
membrane transport of endogenous misfolded substrates is a critical question that 
needs to be addressed by future experiments. In this context, it is worth noting that ER-
to-cytosol membrane transport is central to a major ER-associated degradation pathway 
designed to remove misfolded ER-resident proteins to the cytosol for degradation by the 
proteasome (38). In fact, Hsc70, the J proteins, and Bag2 have already been implicated 
in proteasomal degradation of misfolded substrates (39-42). 
Mechanistically, we demonstrated via cell-based and in vitro approaches that 
Bag2 triggers SV40 release from Hsc70, thereby promoting arrival of SV40 in the 
cytosol. This result is in line with Bag2's established NEF activity, which normally 
converts ADP-Hsc70 to ATP-Hsc70 to trigger substrate release (32). Our data thus 
support the hypothesis that release of SV40 from Hsc70 is necessary for successful 
SV40 arrival in the cytosol. 
We previously found that Hsp105 is a crucial factor that stimulates cytosol entry 
of SV40 from the ER (4). Because Hsp105 can also act as a NEF of Hsc70 (35-37), we 
asked if Hsp105 and Bag2 displayed overlapping functions and found that they did. 
However, it is clear that neither NEF is sufficient to support SV40 infection or ER-to-
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cytosol transport of the virus. Why might ER-to-cytosol transport of SV40 require two 
distinct NEFs that display overlapping functions? One possibility is that a threshold level 
of NEFs beyond what is normally provided by Bag2 or Hsp105 alone is necessary for 
efficient ER-to-cytosol membrane extraction of SV40. Having both Bag2 and Hsp105 
thus provides a sufficiently high level of NEF to carry out the substrate release reaction. 
However, the observation that the HspBP1 NEF is not involved in SV40 ER membrane 
penetration (4) suggests that only selective cytosolic NEFs that are membrane 
associated are strategically positioned to extract the virus from the ER into the cytosol. 
Another possibility is that the different cell types infected by SV40 may harbor only one 
of the two NEFs, and thus, having multiple NEFs capable of regulating the same SV40 
entry step would ensure successful infection. The simultaneous use of two NEFs to 
cross the ER membrane is not unprecedented. In fact, cholera toxin requires both ER-
resident NEFs, Sil1 and Grp170, to penetrate the ER membrane during the toxin's 
cellular-intoxication process (43). 
Single knockdown of either Bag2 or Hsp105 robustly impaired SV40 infection, 
indicating that both Bag2 and Hsp105 play critical roles during SV40 infection. Double 
knockdown of Bag2 and Hsp105 did not cause a more severe block in infection than the 
single-knockdown condition, although this may reflect the sensitivity of the infection 
assay. Regardless, this finding suggests that Bag2 and Hsp105 operate within the same 
pathway during SV40 entry. Because each Hsc70 interacts with only one NEF (through 
its single ATPase domain) at any one point and Bag2 and Hsp105 engage different 
Hsc70 complexes (this study), the simplest model for these data is that an individual 
SV40 particle simultaneously recruits multiple Bag2-Hsc70 and Hsp105-Hsc70 protein 
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complexes, as depicted in Fig. 3-7; the inclusion of SGTA in this model is based on our 
previous findings (3). We envision that iterative cycles of binding to and release from 
these Hsc70-dependent complexes provide the energy to extract SV40 from the ER into 
the cytosol. In sum, our work here identifies a novel member of a cytosolic protein 
complex that extracts a nonenveloped virus across a host membrane, which enables its 
cytosolic entry to cause infection, and provides further insights into this largely 
enigmatic process. 
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Chapter 3 Figures  
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FIG 3-1 Bag2 binds to ER membrane J proteins. 
 
 (A) Total numbers of peptides corresponding to B12, C18, and Bag2 identified by mass 
spectrometry using 3FLAG-B12- or 3FLAG-C18-immunoprecipitated material from HEK 
293T cells.  
(B) HEK 293T cells were transfected with either GFP-S, B12-S, B14-S, or C18-S. The 
cells were lysed, and the resulting cell extracts were subjected to affinity purification and 
SDS-PAGE, followed by immunoblotting using the indicated antibodies. Input 
represents 8% of the total sample used for affinity purification.  
(C) HEK 293T cell extracts were incubated with an anti-B12 or a control IgG antibody. 
The immunoprecipitated (IP) materials were subjected to SDS-PAGE, followed by 
immunoblotting using the indicated antibodies.  
(D) As for panel C, except that HEK 293T cells were transfected with GFP-FLAG, B12-
FLAG, or QPD B12-FLAG, and the cell extracts were incubated with FLAG antibody-
conjugated agarose beads. The asterisk indicates an unidentified protein that cross-
reacted with the Hsc70 antibody.  
(E) As for panel C, except that HEK 293T cells were transfected with GFP-FLAG, WT 
Bag2*-FLAG, or I160A Bag2*-FLAG, and the cell extracts were incubated with FLAG 
antibody-conjugated agarose beads. 
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FIG 3-2 Bag2 promotes SV40 infection. 
  
(A) siRNA knockdown of Bag2 and Hsp105. Cell extracts derived from CV-1 cells 
transfected with the indicated siRNA(s) were subjected to SDS-PAGE and 
immunoblotting with the indicated antibodies. The asterisk indicates an unidentified 
protein that cross-reacted with the actin antibody.  
(B) CV-1 cells transfected with the indicated siRNAs were infected with SV40; 24 hpi, 
the cells were permeabilized, fixed, and stained for large T antigen. At least 300 cells 
were counted per condition over three biological replicates. The graph represents 
means and SD. Student’s two-tailed t test was used to determine statistical significance. 
(C) As for panel B, except cells were transfected with the indicated constructs 24 h prior 
to infection with SV40. The cells were then fixed, permeabilized, and stained for large T 
antigen and FLAG. Only cells expressing the FLAG construct were counted. At least 
100 cells were counted per condition over three biological replicates. The graph 
represents means and SD. Student’s two-tailed t test was used to determine statistical 
significance. 
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FIG 3-3 Bag2 is important for ER-to-cytosol transport of SV40.  
 
(A) CV-1 cells transfected with the indicated siRNAs were infected with SV40 and 
subjected to semipermeabilization. The resulting cytosol-, membrane-, and ER-localized 
fractions were subjected to SDS-PAGE and immunoblotting with the indicated 
antibodies. The amount loaded for the cytosol was 50% of the total cytosol fraction, 
whereas the amount loaded for the membrane was 20% of the total membrane fraction. 
Hsp90 and PDI acted as both loading and fractionation controls.  
(B) The VP1 band intensity in the cytosol fraction from panel A was quantified with 
Image J software (National Institutes of Health), normalized relative to the Hsp90 
loading control bands, and graphed as a percentage of the VP1 band intensity in the 
scrambled-siRNAtreated sample. The graph represents the means and SD from at least 
3 biological replicates. Student’s two-tailed t test was used to determine statistical 
significance. 
 
 
 
 97 
 
 
 
 
 98 
FIG 3-4 Depletion of Bag2 traps SV40 in the ER-to-cytosol membrane penetration site.  
 
(A) CV-1 cells were transfected with the indicated siRNAs for 48 h, followed by 16 h of 
SV40 infection. The cells were fixed, permeabilized, stained using anti-BAP31 and anti-
VP1 antibodies, and imaged by fluorescence microscopy. The enlarged images (3 
zoom) correspond to the boxed areas in the merged images. The arrowheads indicate 
BAP31 foci.  
(B) The size of the VP1 focus was quantified based on the measured area (in pixels) 
using Image J software. The graph represents the means and SD of at least 30 cells 
counted in at least three biological replicates. Student’s two-tailed t test was used to 
determine statistical significance.  
(C) As for panel A, except cells were transfected with the indicated constructs 24 h prior 
to infection with SV40. The cells were then fixed, permeabilized, and stained using anti-
BAP31, anti-FLAG, or anti-S antibodies. Only cells expressing the indicated FLAG- or 
S-tagged constructs were counted. The data plotted are the numbers of cells with at 
least one BAP31 focus, graphed as a percentage of the scrambled siRNA-treated 
sample. The graph represents the means and SD of at least 100 cells counted in at 
least three biological replicates. Student’s two-tailed t test was used to determine 
statistical significance.  
(D) Representative images of the data in panel C. The arrowheads indicate BAP31 foci. 
The asterisks indicate cells expressing the indicated constructs. 
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FIG 3-5 Bag2 releases SV40 from Hsc70.  
 
(A) COS-7 cells were treated with the indicated siRNAs for 24 h, followed by 
transfection of the Hsc70-S construct. After 24 h, the cells were infected with SV40 for 
16 h, and the resulting cell extracts were subjected to affinity purification, SDS-PAGE, 
and immunoblotting with the indicated antibodies.  
(B) The VP1 band intensity from panel A was quantified with Image J software (National 
Institutes of Health), normalized relative to the affinity-purified Hsc70-S level, and 
graphed as a percentage of the VP1 band intensity in the scrambled-siRNA-treated 
sample. The graph represents the means and SD from three biological replicates. 
Student’s two-tailed t test was used to determine statistical significance.  
(C) Coomassie staining of commercially available Hsc70 and Bag2, along with purified 
SV40. Note that the level of VP2 in the SV40 preparation is below the threshold of 
detection.  
(D) After SV40 was incubated with Hsc70 (in the presence of 1 mM DTT), precipitation 
of SV40 VP1 coprecipitated Hsc70. The SV40-Hsc70 complex was incubated with a 
control buffer containing only ATP, or the indicated amount of Bag2 with ATP, followed 
by reimmunoprecipitation of SV40 VP1. The reimmunoprecipitated material was 
subjected to SDS-PAGE followed by silver staining. 
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FIG 3-6 Bag2 and Hsp105 play overlapping roles.  
 
(A) CV-1 cells were transfected with the indicated siRNAs for 24 h, followed by DNA 
transfection of the indicated FLAG constructs. After 24 additional hours, the cells were 
infected with SV40 for 24 h, fixed, permeabilized, and stained for FLAG and large T 
antigen. Only cells expressing the indicated FLAG constructs were counted. At least 
100 cells were counted per condition over three biological replicates. The graph 
represents means and SD. Student’s two-tailed t test was used to determine statistical 
significance.  
(B) As for panel A, except cells were infected with SV40 for 16 h prior to being fixed, 
permeabilized, and stained for FLAG and BAP31. Only cells expressing the indicated 
FLAG constructs were counted. The graph represents the means and SD of at least 100 
cells counted in at least three biological replicates.  
(C) Representative images of the data in panel B. The arrowheads indicate BAP31 foci. 
The asterisks indicate cells expressing the indicated constructs. 
(D) HEK 293T cells were transfected with the indicated FLAG-tagged constructs and 
lysed, and the resulting cell extract was subjected to immunoprecipitation, SDS-PAGE, 
and immunoblotting with the indicated antibodies. 
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FIG 3-7 The Hsc70-SGTA-Bag2 complex docks on an ER membrane J protein and 
promotes SV40 cytosol entry.  
 
In our model, Hsc70-containing protein complexes dock on an ER membrane J protein, 
such as B12. In association with its cochaperone, SGTA, an Hsc70 molecule recruits 
Bag2 or Hsp105, forming either the Hsc70-SGTA-Bag2 or Hsc70-SGTA-Hsp105 
cytosolic extraction complex. During the final step of SV40’s ER-to-cytosol membrane 
transport, a single membrane-embedded viral particle recruits many copies of either the 
Hsc70-SGTA-Bag2 or Hsc70-SGTA-Hsp105 protein complex. Iterative cycles of SV40 
binding to and release from Hsc70 in turn provide the energy to extract the virus into the 
cytosol. (Inset) Importantly, Bag2 functions to trigger SV40 release from Hsc70 in this 
cycle. Bag2 does this by promoting ADP release from Hsc70, generating ATP-Hsc70, 
which displays low affinity for its substrate, such as SV40. “Focus” refers to the SV40 
cytosol entry site in the ER membrane, where the cytosolic extraction machinery is 
recruited to the ER membrane J protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
References:  
1. Poranen MM, Daugelavicius R, Bamford DH. 2002. Common principles in viral 
entry. Annu Rev Microbiol 56:521–538. 
doi:10.1146/annurev.micro.56.012302.160643. 
 
2. Tsai B. 2007. Penetration of nonenveloped viruses into the cytoplasm. Annu Rev 
Cell Dev Biol 23:23–43. doi:10.1146/annurev.cellbio.23.090506.123454. 
 
3. Walczak CP, Ravindran MS, Inoue T, Tsai B. 2014. A cytosolic chaperone 
complexes with dynamic membrane J-proteins and mobilizes a nonenveloped 
virus out of the endoplasmic reticulum. PLoS Pathog 10:e1004007. 
doi:10.1371/journal.ppat.1004007. 
 
4. Ravindran MS, Bagchi P, Inoue T, Tsai B. 2015. A non-enveloped virus hijacks 
host disaggregation machinery to translocate across the endoplasmic reticulum 
membrane. PLoS Pathog 11:e1005086. doi:10.1371/journal.ppat.1005086. 
 
5. Dalianis T, Hirsch HH. 2013. Human polyomaviruses in disease and cancer. 
Virology 437:63–72. doi:10.1016/j.virol.2012.12.015. 
 
6. DeCaprio JA, Garcea RL. 2013. A cornucopia of human polyomaviruses. Nat 
Rev Microbiol 11:264–276. doi:10.1038/nrmicro2992. 
 
7. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC. 1991. 
Structure of simian virus 40 at 3.8-A resolution. Nature 354:278–284. 
doi:10.1038/354278a0. 
 
8. Stehle T, Yan Y, Benjamin TL, Harrison SC. 1994. Structure of murine 
polyomavirus complexed with an oligosaccharide receptor fragment. Nature 
369:160–163. doi:10.1038/369160a0. 
 
9. Stehle T, Gamblin SJ, Yan Y, Harrison SC. 1996. The structure of simian virus 
40 refined at 3.1 A resolution. Structure 4:165–182. doi:10.1016/S0969-
2126(96)00020-2. 
 
10. Chen XS, Stehle T, Harrison SC. 1998. Interaction of polyomavirus internal 
protein VP2 with the major capsid protein VP1 and implications for participation 
of VP2 in viral entry. EMBO J 17:3233–3240. doi:10.1093/emboj/17.12.3233. 
 
11. Smith AE, Lilie H, Helenius A. 2003. Ganglioside-dependent cell attachment and 
endocytosis of murine polyomavirus-like particles. FEBS Lett 555:199–203. 
doi:10.1016/S0014-5793(03)01220-1. 
 
 
 106 
12. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapoport TA. 2003. 
Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 
22:4346–4355. doi:10.1093/emboj/cdg439. 
 
13. Campanero-Rhodes MA, Smith A, Chai W, Sonnino S, Mauri L, Childs RA, 
Zhang Y, Ewers H, Helenius A, Imberty A, Feizi T. 2007. N-glycolyl GM1 
ganglioside as a receptor for simian virus 40. J Virol 81:12846–12858. 
doi:10.1128/JVI.01311-07. 
 
14. Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A. 
2011. Role of endosomes in simian virus 40 entry and infection. J Virol 85:4198–
4211. doi:10.1128/JVI.02179-10. 
 
15. Qian M, Cai D, Verhey KJ, Tsai B. 2009. A lipid receptor sorts polyomavirus from 
the endolysosome to the endoplasmic reticulum to cause infection. PLoS Pathog 
5:e1000465. doi:10.1371/journal.ppat.1000465. 
 
16. Kartenbeck J, Stukenbrok H, Helenius A. 1989. Endocytosis of simian virus 40 
into the endoplasmic reticulum. J Cell Biol 109:2721–2729.  
 
17. Geiger R, Andritschke D, Friebe S, Herzog F, Luisoni S, Heger T, Helenius A. 
2011. BAP31 and BiP are essential for dislocation of SV40 from the endoplasmic 
reticulum to the cytosol. Nat Cell Biol 13:1305–1314. doi:10.1038/ncb2339. 
 
18. Clever J, Yamada M, Kasamatsu H. 1991. Import of simian virus 40 virions 
through nuclear pore complexes. Proc Natl Acad Sci U S A 88:7333–7337. 
doi:10.1073/pnas.88.16.7333. 
 
19. Nakanishi A, Clever J, Yamada M, Li PP, Kasamatsu H. 1996. Association with 
capsid proteins promotes nuclear targeting of simian virus 40 DNA. Proc Natl 
Acad Sci U S A 93:96–100. doi:10.1073/pnas.93.1.96. 
 
20. Magnuson B, Rainey EK, Benjamin T, Baryshev M, Mkrtchian S, Tsai B. 2005. 
ERp29 triggers a conformational change in polyomavirus to stimulate membrane 
binding. Mol Cell 20:289–300. doi:10.1016/j.molcel.2005.08.034. 
 
21. Gilbert J, Ou W, Silver J, Benjamin T. 2006. Downregulation of protein disulfide 
isomerase inhibits infection by the mouse polyomavirus. J Virol 80:10868–10870. 
doi:10.1128/JVI.01117-06. 
 
22. Schelhaas M, Malmstrom J, Pelkmans L, Haugstetter J, Ellgaard L, Grunewald 
K, Helenius A. 2007. Simian virus 40 depends on ER protein folding and quality 
control factors for entry into host cells. Cell 131:516–529. 
doi:10.1016/j.cell.2007.09.038. 
 
 107 
23. Walczak CP, Tsai B. 2011. A PDI family network acts distinctly and coordinately 
with ERp29 to facilitate polyomavirus infection. J Virol 85:2386–2396. 
doi:10.1128/JVI.01855-10. 
 
24. Inoue T, Dosey A, Herbstman JF, Ravindran MS, Skiniotis G, Tsai B. 2015. 
ERdj5 reductase cooperates with protein disulfide isomerase to promote simian 
virus 40 endoplasmic reticulum membrane translocation. J Virol 89:8897–8908. 
doi:10.1128/JVI.00941-15. 
 
25. Daniels R, Rusan NM, Wadsworth P, Hebert DN. 2006. SV40 VP2 and VP3 
insertion into ER membranes is controlled by the capsid protein VP1: implications 
for DNA translocation out of the ER. Mol Cell 24:955–966. 
doi:10.1016/j.molcel.2006.11.001. 
 
26. Rainey-Barger EK, Magnuson B, Tsai B. 2007. A chaperone-activated 
nonenveloped virus perforates the physiologically relevant endoplasmic reticulum 
membrane. J Virol 81:12996–13004. doi:10.1128/JVI.01037-07. 
 
27. Kuksin D, Norkin LC. 2012. Disassembly of simian virus 40 during passage 
through the endoplasmic reticulum and in the cytoplasm. J Virol 86:1555–1562. 
doi:10.1128/JVI.05753-11. 
 
28. Dupzyk A, Williams JM, Bagchi P, Inoue T, Tsai B. 2017. SGTA-dependent 
regulation of Hsc70 promotes cytosol entry of Simian Virus 40 from the 
endoplasmic reticulum. J Virol 12:e00232-17. doi:10.1128/JVI.00232-17. 
 
29. Goodwin EC, Lipovsky A, Inoue T, Magaldi TG, Edwards AP, Van Goor KE, 
Paton AW, Paton JC, Atwood WJ, Tsai B, DiMaio D. 2011. BiP and multiple 
DNAJ molecular chaperones in the endoplasmic reticulum are required for 
efficient simian virus 40 infection. mBio 2:e00101-11. doi:10.1128/mBio.00101-
11. 
 
30. Bagchi P, Walczak CP, Tsai B. 2015. The endoplasmic reticulum membrane J 
protein C18 executes a distinct role in promoting simian virus 40 membrane 
penetration. J Virol 89:4058–4068. doi:10.1128/JVI.03574-14. 
 
31. Inoue T, Tsai B. 2017. Regulated Erlin-dependent release of the B12 
transmembrane J-protein promotes ER membrane penetration of a non-
enveloped virus. PLoS Pathog 13:e1006439. doi:10.1371/journal.ppat.1006439. 
 
32. Xu Z, Page RC, Gomes MM, Kohli E, Nix JC, Herr AB, Patterson C, Misra S. 
2008. Structural basis of nucleotide exchange and client binding by the Hsp70 
cochaperone Bag2. Nat Struct Mol Biol 15:1309–1317. doi:10.1038/nsmb.1518. 
 
 108 
33. Inoue T, Tsai B. 2011. A large and intact viral particle penetrates the 
endoplasmic reticulum membrane to reach the cytosol. PLoS Pathog 
7:e1002037. doi:10.1371/journal.ppat.1002037. 
 
34. Rauch JN, Gestwicki JE. 2014. Binding of human nucleotide exchange factors to 
heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro. 
J Biol Chem 289:1402–1414. doi:10.1074/jbc.M113.521997. 
 
35. Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU. 2006. Molecular 
chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. 
EMBO J 25:2519–2528. doi:10.1038/sj.emboj.7601138. 
 
36. Raviol H, Bukau B, Mayer MP. 2006. Human and yeast Hsp110 chaperones 
exhibit functional differences. FEBS Lett 580:168–174. 
doi:10.1016/j.febslet.2005.11.069. 
 
37. Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P. 2013. Hsp110 is a bona 
fide chaperone using ATP to unfold stable misfolded polypeptides and 
reciprocally collaborate with Hsp70 to solubilize protein aggregates. J Biol Chem 
288:21399–21411. doi:10.1074/jbc.M113.479253.. 
 
38. Berner N, Reutter KR, Wolf DH. 2 February 2018. Protein quality control of the 
endoplasmic reticulum and ubiquitin-proteasome-triggered degradation of 
aberrant proteins: yeast pioneers the path. Annu Rev Biochem. 
doi:10.1146/annurev-biochem-062917-012749. 
 
39. Arndt V, Daniel C, Nastainczyk W, Alberti S, Hohfeld J. 2005. BAG-2 acts as an 
inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol Biol Cell 
16:5891–5900. doi:10.1091/mbc.e05-07-0660. 
 
40. de Paula CA, Santiago FE, de Oliveira AS, Oliveira FA, Almeida MC, Carrettiero 
DC. 2016. The co-chaperone BAG2 mediates cold-induced accumulation of 
phosphorylated tau in SH-SY5Y cells. Cell Mol Neurobiol 36:593–602. 
doi:10.1007/s10571-015-0239-x. 
 
41. Qin L, Guo J, Zheng Q, Zhang H. 2016. BAG2 structure, function and 
involvement in disease. Cell Mol Biol Lett 21:18. doi:10.1186/s11658-016-0020-
2. 
42. Schonbuhler B, Schmitt V, Huesmann H, Kern A, Gamerdinger M, Behl C. 2016. 
BAG2 interferes with CHIP-mediated ubiquitination of HSP72. Int J Mol Sci 
18:E69. doi:10.3390/ijms18010069. 
 
43. Williams JM, Inoue T, Chen G, Tsai B. 2015. The nucleotide exchange factors 
Grp170 and Sil1 induce cholera toxin release from BiP to enable 
retrotranslocation. Mol Biol Cell 26:2181–2189. doi:10.1091/mbc.e15-01-0014. 
 
 109 
Chapter 4: The g-secretase binding-partner p120 catenin promotes HPV infection 
 
Introduction 
Human papillomaviruses (HPVs) are one of the most common sexually 
transmitted pathogens, and account for nearly all cases of cervical, anogenital, and 
oropharyngeal cancers (1). Despite a highly effective prophylactic vaccine against 7 
high-risk and 2 low-risk HPVs, the virus still causes morbidity and mortality as a result of 
limited access to the vaccine itself, as well as an inability to combat disease in 
individuals already exposed to HPV (1, 2). Hence, clarifying HPV cell entry remains 
imperative as this might identify new therapeutic strategies.   
Structurally, HPV is a nonenveloped DNA tumor virus composed of 72 
pentamers of the major capsid protein L1 (3). Underlying L1 is the minor capsid protein 
L2 that varies in copy number (3). Protected inside the L1 pentamers is the 8-kilobase 
pair circular double-stranded DNA genome (4). HPV infection begins when L1 interacts 
with heparin sulfate proteoglycans on the plasma membrane or extracellular matrix (5-
8). This stimulates viral conformational changes that allow the furin protease to cleave 
the N-terminus of L2 (7-11). The virus is then thought to be transferred to an unknown 
entry receptor, which initiates receptor-mediated endocytosis delivering HPV to the 
endosome (12). The low pH in this compartment, in conjunction with the peptidylprolyl 
isomerase cyclophilin, promotes partial uncoating of HPV, resulting in release of the 
majority of the L1 pentamers from the L2-viral genome complex (13, 14). Exposure of 
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L2 in turn enables this viral protein to insert into the endosomal membrane (15-
18). Importantly, we demonstrated that the transmembrane protease g-secretase 
promotes membrane insertion of L2 (18). L2 membrane insertion exposes the C-
terminus of L2 (that harbors a retromer-binding motif) to the cytosol (19, 20). This then 
recruits the cytosolic retromer complex to HPV that routes the virus to the trans Golgi 
network (TGN) and then the Golgi (21-24). HPV remains in this compartment until 
mitosis, when it buds from the Golgi, trafficking to the nucleus to cause infection (25-
29). As HPV in the endosome can also sort to the lysosome for degradation, the ability 
of the virus to target along the endosome-Golgi axis represents the committed infection 
step (30, 31). Within the endosome-Golgi axis, the decisive step is g-secretase-
dependent insertion of L2 into the endosome membrane (18, 32, 33, 34). In this context, 
a critical question is: how is HPV targeted to the g-secretase complex?  
Using an unbiased biochemical proteomics approach, our lab identified a 
cytosolic protein called p120 catenin (p120) as a potential novel binding partner of HPV 
L2 during virus entry (18). p120 belongs to the catenin family well-established for their 
interactions with cell surface-localized transmembrane adhesion receptors called 
cadherins (35-37). Importantly, p120 is also known to bind to g-secretase (38). In fact, 
one crucial cellular function of p120 is to target cadherins to g-secretase, enabling this 
transmembrane protease to cleave cadherins essential to elicit a cellular response (39). 
Here, using a loss-of-function strategy, we demonstrate that p120 promotes HPV 
infection by targeting the virus from the cell surface to g-secretase in the endosome, 
thereby enabling g-secretase to insert HPV L2 into the endosome membrane – a critical 
event during productive HPV entry. As HPV is not exposed to the cytosol at the cell 
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surface, the observed HPV-p120 interaction at the cell surface is likely mediated by an 
unknown receptor. We propose that the receptor-p120 complex engages HPV at the 
plasma membrane, delivering HPV to g-secretase when the receptor-p120 complex 
itself is recruited to g-secretase. 
 
Materials and Methods 
Antibodies and Inhibitors 
 
M2 FLAG antibody was purchased from Sigma (St. Louis, MO). The p120 antibody was 
purchased from Santa Cruz Biotech (Santa Cruz, Ca). Antibody against the C-terminal 
fragment of PS1 was purchased from Cell Signaling Technologies (Danvers, MA). Anti-
PD1 antibody was purchased from Abcam (Cambridge, MA). Anti-Bap31 antibody was 
purchased from Invitrogen (Carlsbad, CA) and anti- B actin antibody was purchased 
from Cell Signaling (Danvers, MA). The g-secretase inhibitor XXI was purchased from 
Millipore and dissolved in DMSO and used at a concentration of 1µM.  
 
DNA Constructs 
 
The p16sheLL plasmid was a gift from Dr. John Shiller (National Cancer Institute, 
Rockville, MD; plasmid 37320, Addgene). The p16sheLL was used as in Zhang et al., 
2014 (35) to produce the WT HPV16.L2F pseudovirus (PsV) with FLAG tagged L2, and 
WT HPV16 L1.   
 
Cells 
 
HeLa cells were purchased from American Type Culture Collection. The 293TT cells 
were a generous gift from Dr. Christopher Buck (National Cancer Institute, Rockville, 
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MD). Cells were cultured in DMEM (Thermo Fisher Scientific) and 10% fetal bovine 
serum (Corning) containing 10 mg/ml streptomycin and 10 U/ml penicillin (Thermo 
Fisher Scientific).    
 
Pseudovirus Production  
 
WT HPV16.L2F was produced according to Inoue et al., 2018 (33).   Briefly, 293TT cells 
were co-transfected with p16sheLL.L2F along with indicated reporter construct (Gaussia 
luciferase or GFP-S) with polyethyleneimine (Polysciences Inc.). After 48 hrs, cells were 
harvested, lysed in 0.5% triton X-100, 10mM MgCl2, 5mM CaCl2, and 0.5 U/ml RNase 
A. Lysate was centrifuged on an optiprep gradient of 27, 33, and 39% at 300,000 g for 4 
hours, at 16 ˚C, in a SW55 Ti rotor.  
 
siRNA Transfection 
 
siRNAs used in this study target the following sequences: PS1 siRNA: 5’- 
UCAAGUACCUCCCUGAAUG-3’; p120 siRNA: 5’-GCUAUGAUGACCUGGAUUA-3’. As 
a negative control, Allstar siRNA (Qiagen) was used. HeLa cells were seeded and 
simultaneously transfected (reverse transfected) with 75-100 nM siRNA using 
Lipofectamine RNAi MAX (Thermo Fisher Scientific) and incubated for at least 48 hours 
prior to infection or 24 hours prior to biochemical assays.  
 
Infection studies 
 
HeLa cells were seeded in 6 well plates and reverse transfected with indicated siRNAs 
for 72 hours, followed by infection with HPV16.L2F PsV  (MOI~ 9-10) containing a 
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reporter plasmid encoding secreted Gaussia luciferase. Cells were treated with DMSO 
or compound XXI (1 µM) in DMSO at time of infection. At 48 hpi, 10 µl of supernatant 
was collected from each well and luciferase activity was measured using BioLux 
Gaussia Luciferase Assay Kit (NEB) according to manufacturer’s instructions.  
 
Immunoprecipitation of HPV16.L2F/ Mass Spectrometry  
 
Immunoprecipitation of HPV16.L2F was performed as in Inoue et al., 2018 (18). Briefly, 
HeLa cells were infected or uninfected for 16 hrs before being lysed in 1% triton-X-100 
in HN buffer (50mM Hepes, pH 7.5, 150 mM NaCl) and 1mM PMSF. After 
centrifugation, cell lysate was incubated with M2-FLAG antibody (0.3 µg/ml) for 2 hrs at 
4˚C, followed by incubation with protein G-coated magnetic Dynabeads (Thermo Fisher 
Scientific). In the case of uninfected cells, lysates were mixed with purified PsV and 
functioned as a background control for post lysis binding. Proteins were eluted from 
beads using 0.1 mg/ml 3X FLAG peptide, followed by TCA precipitation. TCA- 
precipitated proteins were sent for mass spectrometry analysis (Taplin Mass 
Spectrometry Core Facility, Harvard Medical School).  
 
Immunoprecipitation 
 
HeLa cells were plated at 5 x 106 in 10 cm plates and incubated overnight. Cells were 
then infected with WT HPV16.L2F PsV (MOI ~100) for indicated times before lysis in 
1% Decyl Maltose Neopenyl Glycol (DMNG) (Anatrace) in HN buffer and 1 mM PMSF. 
Lysed cells were centrifuged at 16,100 g for 10 min and resulting supernatant was 
incubated with M2 FLAG antibody overnight at 4˚C, rotating. Supernatant plus antibody 
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was then added to protein G-coated magnetic dynabeads for 1 hr at 4˚C, rotating. 
Beads were washed 3X in 0.1% DMNG in HN buffer. Beads were incubated at 95˚C for 
10 minutes with 5X SDS sample buffer plus 2-mercaptoethanol (BME) and subjected to 
SDS-PAGE and immunoblotting with the indicated antibodies. Alternatively, cells were 
seeded and reverse transfected with indicated siRNAs for at least 24 hours prior to 
infection (Fig. 4-3A) before treatment as above. The bar graph in Fig. 4-3A shows 
relative values of L2-FLAG co-immunoprecipitated with PS1, where L2-FLAG co-
immunoprecipitated with PS1 in scrambled siRNA treated cells is set to 100%. Values 
are normalized to PS1 band intensities. Bars represent the means ± standard deviations 
of at least three biological replicates. Significance determined using student’s t test.  
 
Alkali extraction assay 
 
As in Inoue et al., (18), briefly, HeLa cells were seeded at 2.0 x 106 cells in 6 cm plates 
and infected with WT HPV16.L2F (MOI ~40-50) for 16 hrs. After 16 hrs, cells were 
collected and resuspended in HN buffer before being homogenized in 10 µM clearance 
ball bearing homogenizer (Isobiotech). Cell homogenate was then centrifuged at 16,100 
x g, at 4˚C, for 10 min. Resulting supernatant was then centrifuged at 50,000 rpm, 4˚C, 
for 30 min in a TLA 100.3 rotor (Beckman). Pellet was treated with 25 µl of 10mM Tris-
HCl (pH 7.5), 150 mM NaCl, 2mM MgCl2, with 5mM DTT, and 50 units of Benzonase.  
This was incubated at 37˚C for 30 min. After 30 min, 225 µl of 0.1M Na2CO3 and 2 M 
Urea was added and incubated at 4˚C for 10 min. Next samples were centrifuged at 
50,000 rpm, 4˚C for 30 min. Supernatant fraction was collected, and pellet was rinsed in 
HN buffer, and recentrifuged. Pellet and supernatant fraction were incubated at 95˚C for 
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10 min with 5X SDS running buffer plus BME, then subjected to SDS-PAGE and 
immunoblot with indicated antibodies. For quantification in Fig. 4-3B, bars represent 
relative values of L2-FLAG in pellet fraction, compared to L2-FLAG quantity in pellet 
fraction of scrambled siRNA treated cells, which is set to 100%. Values are normalized 
to Bap31 band intensities. Bars represent the means ± standard deviations of at least 
three biological replicates. Significance determined using student’s t test.  
 
Results 
p120 binds to HPV16 L2 and promotes infection.  
In order to study HPV entry and infection, we used a HPV16 pseudovirus (PsV) 
system composed of L1 and a C-terminally FLAG-tagged L2 encapsulating a luciferase 
reporter construct (WT HPV16.L2F) (3, 40). HPV16 PsV infection has been previously 
shown to mimic authentic HPV16 entry (3, 40). Using this PsV system in the context of 
an unbiased proteomics approach, we sought to identify host factors that bind to HPV16 
L2 during entry. In this approach, an extract prepared from HeLa cells infected with WT 
HPV16.L2F was subjected to immunoprecipitation using an antibody against FLAG, and 
the bound material was eluted and analyzed by mass spectrometry (18). As a negative 
control, an extract prepared from uninfected HeLa cells was incubated with purified 
HPV16.L2F, and subjected to FLAG immunoprecipitation followed by mass 
spectrometry analysis; cellular proteins that bind to HPV16 L2 under this condition 
occurred during the extraction process, and are unlikely to represent factors that interact 
with the virus during entry. 
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Our results indicated that in addition to peptides corresponding to all 4 subunits 
of the g-secretase complex (PS1, NICA, APH1A, and PEN2), 14 peptides corresponding 
to p120 catenin were present in the immunoprecipitated sample derived from the WT 
HPV16.L2F-infected extract (Fig. 4-1A); no peptides matching p120 were found in the 
sampled generated from the uninfected extract. Presence of p120 in the 
immunoprecipitated sample from the WT HPV16.L2F infected cells was verified by 
immunoblotting (Fig. 4-1B), demonstrating that HPV binds to p120. Importantly, when 
p120 was depleted via the siRNA approach in HeLa cells (Fig. 4-1C), WT HPV16.L2F 
infection was significantly attenuated (Fig. 4-1D), similar to the effect of knocking down 
PS1, as previously reported (18). These results indicate that p120 interacts with HPV-L2 
and promotes HPV16 infection.  
 
p120 binds to HPV16 L2 during early infection.  
We next performed a time course experiment to assess when WT HPV16.L2F 
engages p120 during entry. HeLa cells incubated with WT HPV16.L2F for the indicated 
times were harvested, and the resulting cell extracts were subjected to 
immunoprecipitation using an antibody against FLAG. The bound material was analyzed 
by SDS-PAGE and immunoblotting. We found that p120 binds to the virus at the time of 
infection (0 hpi), with this interaction gradually disappearing after 7 hpi (Fig. 4-2A). 
Because previous studies showed that HPV reaches endosomal compartments 6-7 hpi, 
these findings suggest that p120 initiates binding to HPV at the cell surface, losing its 
affinity for the virus when HPV reaches the endosome (31, 41, 42). By contrast, g-
secretase (PS1) is reported to efficiently engage the virus only after 6 hpi (18). Thus, 
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HPV16 L2 interacts with p120 early during infection before the virus is recruited to the g-
secretase complex. 
 
p120 promotes g-secretase-dependent membrane insertion of HPV16 L2.  
Our time course experiment revealed that as p120 binding to HPV16 L2 
decreases, a corresponding increase in the g-secretase-L2 interaction is observed, 
raising the possibility that p120 is required for L2 to target to g-secretase. To test this, 
we asked if depleting p120 blocked the g-secretase-L2 interaction, and found that it did 
(Fig. 4-3A, top panel; the extent of decrease is quantified in the right graph). This finding 
is consistent with the idea that p120 targets HPV L2 to g-secretase. 
Upon reaching g-secretase, the L2 protein of HPV16 is inserted into the 
endosome membrane by the newly-ascribed chaperone activity of g-secretase (18). We 
reasoned that if p120 is required to deliver L2 to g-secretase, g-secretase-dependent 
membrane insertion of L2 should similarly decrease when p120 is downregulated. To 
monitor membrane insertion of L2, we used the classic alkali extraction method, a 
rigorous biochemical approach that assesses whether a protein is a bona fide 
transmembrane protein. In this assay, WT HPV16.L2F-infected HeLa cells were 
disrupted mechanically, and the membrane fraction (containing the plasma, endosome, 
Golgi, and ER membranes) are collected by centrifugation. This membrane fraction was 
then resuspended in an alkaline carbonate solution containing the denaturant urea, and 
subjected to another round of centrifugation to produce a supernatant (S) and a pellet 
(P) fraction. Since treatment of alkali only perturbs the integrity of the membrane without 
affecting the ability of a transmembrane protein to remain as a membrane-inserted 
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protein, soluble luminal proteins (including protein disulfide isomerase [PDI]) can be 
found in the S fraction, while transmembrane proteins (including BAP31) reside in the P 
fraction (Fig. 4-3B). Thus, in this assay, L2 in the P fraction represents the membrane 
inserted form of L2. Importantly, the level of L2 in the P fraction markedly decreased 
when p120 was depleted (Fig. 4-3B, top panel; the extent of decrease is quantified in 
the graph to the right), indicating that in the absence of p120, HPV16 L2 fails to insert 
into the endosome membrane. This is consistent with the observation that p120 
depletion blocks the interaction between L2 and g-secretase (Fig. 4-3A). Together, our 
data suggest a scenario in which p120 targets HPV16 L2 to g-secretase, thereby 
enabling g-secretase to promote insertion of L2 into the endosome membrane – a 
critical infection step. 
 
 
Discussion 
 
High risk HPVs are the primary cause of cervical cancer worldwide and are 
associated with increasing rates of anogenital and oropharyngeal cancers. Despite 
HPV’s significant impact on human health, much remains unknown regarding its 
infectious cellular entry. Upon receptor-mediated endocytosis, HPV reaches the 
endosome and is sorted to the Golgi en route for successful infection (12, 21-24). As 
endosome-localized HPV can also traffic to the lysosome where it is degraded, 
transport along the endosome-Golgi axis represents the productive entry route (30, 31). 
The decisive event in endosome-to-Golgi targeting of HPV is insertion of the HPV L2 
protein into the endosome membrane (18). This is because upon membrane insertion, 
L2 is exposed to the cytosol, which in turn recruits the cytosolic retromer complex that 
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directs the virus to the Golgi (16, 18, 19-21). The mechanism by which L2 is inserted 
into the endosome membrane was recently revealed by our lab, demonstrating that the 
transmembrane protease g-secretase in the endosome binds to and inserts L2 into the 
membrane (18). Despite this finding, how HPV is delivered to the g-secretase complex 
remains enigmatic. 
This study identified p120 catenin, an established binding-partner of g-secretase, 
as a host cytosolic factor that promotes HPV16 infection (38). Mechanistically, it does 
so by targeting HPV16 L2 to g-secretase, enabling g-secretase to insert L2 into the 
endosome membrane. Our results demonstrate that the p120-HPV16 L2 interaction 
begins at the earliest time points during infection when the virus is localized to the cell 
surface. However, HPV16 L2 is not exposed to the cytosol until it is endocytosed and 
reaches the endosome. How then can p120 interact with HPV16 L2 at the plasma 
membrane? To reconcile this, we hypothesize that p120 must engage the virus via a 
transmembrane receptor.  
We envision two models by which p120 targets HPV16 L2 to the endosome-
localized g-secretase. In the first model, p120 actively regulates initial endocytosis of 
HPV16 bound to the receptor-p120 complex at the plasma membrane, thereby 
promoting arrival of the viral particle to the endosome (Fig. 4-4A). In the second model, 
p120 exerts its role post endosome-arrival. Specifically, within the endosome, p120 
targets HPV16 bound to the receptor-p120 complex to g-secretase, delivering the virus 
to g-secretase (Fig. 4-4B). We note that models 1 and 2 do not have to be exclusive: it is 
entirely possible that p120 exerts its action both at the step of initial endocytosis and in 
delivery of the virus to g-secretase within the endosome. Clearly, additional experiments 
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are required to distinguish between these models. Regardless of the model, p120 
clearly controls a critical infectious entry step. In this context, we recognize that while 
there are likely numerous host factors that also trigger endocytosis of HPV16, the 
subsequent intracellular transport pathways often result in a non-infectious fate.  
In sum, our work here begins to reveal the mechanistic basis by which HPV16 is 
sorted from the endosome to the Golgi, the committed step in HPV entry. By identifying 
a new host component that supports HPV infection, these results should provide 
additional strategies to combat HPV-induced diseases. 
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Chapter 4 Figures  
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Figure 4-1 p120 binds HPV L2 and promotes infection. 
 
A) Hela cells were infected, or mock infected with HPV16.L2F pseudovirus and L2-
FLAG was immunoprecipitated. Immunoprecipitated samples were subjected to 
mass spectrometry. CTND1: gene encoding p120 catenin.  
B) Hela cells were infected with HPV16.L2F pseudovirus or treated with DMSO for 6 
hrs before a 1% DMNG lysis, and immunoprecipitation using M2 FLAG antibody and 
protein G dynabeads. Immunoprecipitated (IP) samples were subjected to SDS-
PAGE and immunoblotting with indicated antibodies. Input represents 10% of whole 
cell lysate (WCL).  
C) Hela cells were seeded and simultaneously transfected with indicated siRNAs. After 
48 hrs, cells were lysed in 1% DMNG and WCL was subjected to SDS-PAGE and 
immunoblotting with indicated antibodies. PS1 (CTF): PS1 C terminal fragment.  
D) Hela cells were seeded and transfected with indicated siRNA for 72 hrs, followed by 
48 hr infection with HPV16.L2F pseudovirus. Alternatively, cells treated with 
compound XXI were simultaneously infected. HPV16.L2F infection was monitored 
by luciferase activity in culture supernatant. The graph represents relative value to 
cells transfected with control siRNA, which is set to 100%. Bars represent the means 
± standard deviations from at least 3 biological replicates. Student’s two-tailed t test 
was used to determine statistical significance.  
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Figure 4-2 The HPV L2 protein binds to p120 prior to engaging g-secretase. 
 
A) Hela cells were infected with HPV16.L2F (MOI~100) for the indicated times. Cells 
were harvested and lysed in 1% DMNG. L2-FLAG was immunoprecipitated from 
lysates and subjected to SDS-PAGE and immunoblotting with indicated antibodies. 
Input represents 10% of WCL.  
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Figure 4-3 p120 promotes g-secretase-dependent insertion pf HPV16 L2.  
 
A) HeLa cells were seeded and simultaneously transfected with indicated siRNA for 24 
hrs. After 24 hrs, cells were infected with HPV16.L2F (MOI~50) for 16 hrs before 
lysis in 1% DMNG. PS1 was immunoprecipitated from lysates and subjected to 
SDS-PAGE and immunoblotting with indicated antibodies. Input represents 10% of 
WCL. Graph: values are relative to PS1-L2 FLAG binding in cells treated with 
scrambled siRNA, which is set to 100%, after PS1 normalization. Bars represent the 
means ± standard deviations from at least 3 biological replicates. Student’s two-
tailed t test was used to determine statistical significance. 
B) HeLa cells were seeded and simultaneously transfected with indicated siRNA for 24 
hrs, followed by 16 hr infection with HPV16.L2F (MOI~50). After 16 hrs, cells were 
homogenized and membrane fraction was separated from cytosolic, mitochondria 
and nuclear fraction using centrifugation. Pellet fraction was treated with alkali 
reagents (pH ~11) with urea and DTT. Resulting fractions (P, pellet; S, supernatant) 
were subjected to SDS-PAGE and immunoblotting with the indicated antibodies. The 
amount loaded for the pellet fraction was 50% of the total pellet fraction. The amount 
loaded for the supernatant fraction was 7.5% of the total supernatant fraction. Bar 
graph represents means ± standard deviations from at least 3 biological replicates, 
and is relative to L2-FLAG level in pellet fraction of scrambled siRNA treated cells, 
which is set to 100%. Data are normalized to Bap31 levels.  Student’s two-tailed t 
test was used to determine statistical significance. 
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Fig. 4-4. Model of p120 promoting HPV infection.  
 
A) In model A, p120 is necessary for HPV endocytosis. Upper graphic: HPV binds to 
HSPG (attachment receptor, purple) at the plasma membrane. After capsid 
conformational changes, HPV binds to the unknown entry receptor (red). P120 
promotes endocytosis of the HPV-entry receptor complex. In the endosome, the 
HPV-receptor complex, along with p120, bind to g-secretase (blue in endosomal 
membrane) for g-secretase-mediated L2 insertion into the endosomal membrane, a 
decisive step in infection. HPV then traffics along the productive infection route to 
the trans golgi network (TGN) and the nucleus. Without p120 (lower graphic), HPV 
and the unknown entry receptor are not endocytosed, consequently, infection does 
not occur.  
B) In model B, p120 targets HPV to g-secretase. Upper graphic: HPV binds to HSPG 
(attachment receptor) at the plasma membrane. After capsid conformational 
changes, HPV binds to the unknown entry receptor. Although p120 associates with 
the unknown entry receptor, it is not necessary for HPV endocytosis. Once in the 
endosome, p120 targets HPV to g-secretase for g-secretase-mediated L2 insertion 
into the endosomal membrane, a decisive step in infection. HPV then traffics along 
the productive infection route to the trans golgi network (TGN) and the nucleus. 
Lower graphic: Without p120 (lower graphic), HPV and the unknown entry receptor 
are endocytosed, but HPV is not targeted to g-secretase. Because HPV is not 
targeted to g-secretase, L2 is not inserted through the endosomal membrane, and 
therefore unavailable for retromer binding and trans golgi network arrival. 
Consequently, infection does not occur.  
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Chapter 5. Conclusions and Future Directions 
PyV 
A host membrane acts as a critical barrier during entry of nonenveloped viruses 
(1). How these viruses penetrate a cellular membrane remains enigmatic, but insights 
into this process are slowly emerging. For the classic nonenveloped PyV SV40, 
penetration across the ER membrane to reach the cytosol represents the decisive 
infection step. During productive entry, SV40 is initially transported from the cell surface 
to the ER from where it crosses the ER membrane to access the cytosol and then the 
nucleus to cause infection (Fig. 1-1B) (2-9). Upon reaching the ER, host cues including 
the PDI family proteins in this compartment induce conformational changes to SV40, 
generating a hydrophobic viral particle that integrates into the ER membrane (10-14). 
To complete membrane penetration, a cytosolic ternary protein complex composed of 
Hsc70, Bag2, and SGTA, Hsp105 – forming the so-called extraction machinery – 
engages the ER membrane-integrated virus and ejects it into the cytosol (15-19). This 
thesis clarified the molecular basis of SV40’s cytosol extraction process. Specifically, 
my results demonstrated that the Hsc70 chaperone first binds to the ER membrane-
embedded virus. The ability of Hsc70 to engage the virus is due to the action of ER 
membrane J proteins (B12, B14, and C18), which converts low-affinity ATP-Hsc70 to 
high-affinity ADP-Hsc70 (15, 16, 20). Next, acting as a nucleotide exchange factor 
(NEF), Bag2 induces release of SV40 from Hsc70 by switching ADP-Hsc70 back to 
ATP-Hsc70 (19). Iterative rounds of binding and release of SV40 to and from Hsc70 
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“pulls” the virus out of the ER membrane. My analysis also revealed that SGTA 
regulates this Hsc70-dependent substrate binding-release cycle, either by inhibiting the 
activity of the J proteins or stimulating the NEF function (18). Hsp105 is likely involved in 
a reaction that disassembles the membrane-embedded SV40, presumably to enable 
efficient extraction of the virus (17). 
Interestingly, although members of this extraction machinery are also 
components of the ERAD system that normally ejects cellular misfolded proteins from 
the ER into the cytosol, SV40 appears to hijack the extraction machinery in a novel way. 
The major difference is that ERAD substrates transport across the ER membrane by 
passing through a protein-conducting channel (formed by the Hrd1 transmembrane 
protein), while SV40 does not use a protein-based channel but instead penetrates the 
lipid bilayer of the ER to reach the cytosol (15-19, 21).  
This situation raises a major conundrum: with a protein-conducting channel, the 
cytosol extraction machinery has a defined “docking site” where it can be recruited, and 
subsequently engage the translocating substrate (21, 22). However, in a situation where 
SV40 simply penetrates the lipid bilayer of the vast ER membrane network, where does 
the cytosol extraction machinery dock? Part of the explanation may lie in the 
observation that SV40 induces formation of cytosol entry sites in the ER membrane. For 
instance, SV40 triggers reorganization of the transmembrane J proteins B12, B14, and 
C18 to discrete sites in the ER called foci (15,16). Because these J proteins have their 
J-domain facing the cytosol, and because a J-domain binds to Hsc70, we anticipate that 
concentrating the J proteins to the foci should correspondingly recruit the cytosol 
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extraction machinery to the foci (16). Hence, in this scenario, a docking site on the ER 
membrane for the extraction machinery is in fact created by the incoming virus. 
Although our analyses strongly support a model in which Hsc70, Bag2, SGTA, 
and Hsp105 form a ternary protein complex that ejects SV40 from the ER into the 
cytosol, many important questions remain. One obvious question is whether there are 
additional unidentified host factors present in the extraction complex? Addressing this 
question will require more rigorous biochemical approaches. For instance, a “sequential 
co-IP” approach coupled with mass spectrometry analysis should reveal if there are 
additional host factors present in the SV40-extraction machinery complex. In this 
context, establishing an in vitro reconstituted membrane transport system using purified 
cytosolic components will enable us to test whether there are minimum components 
required to drive ER-to-cytosol transport of SV40. Another outstanding question is how 
Hsp105-dependent disassembly of the virus is coupled to the extraction process. Does 
virus disassembly precede extraction, or vice versa?  
One fascinating yet puzzling question surrounding this thesis work is that, while 
SV40 is thought to disguise as a misfolded substrate that hijacks elements of the ERAD 
machinery to gain access to the cytosol, the virus nonetheless escapes the degradative 
fate typically experienced by misfolded proteins in the cytosol. Indeed, how does SV40 
evade the ubiquitin-dependent proteasome machinery once it reaches the cytosol? 
Thus far, none of the SV40 structural proteins have been reported to be 
polyubiquitinated, a post-translational modification appended to a substrate destined for 
proteasomal degradation. If in fact SV40 is not subjected to polyubiquitination, it is 
possible that recruitment of the extraction machinery (or other unidentified cytosolic 
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proteins) physically impedes the cascade of ubiquitination enzymes from gaining access 
to the viral proteins. Careful analysis of any potential post-translational modification 
imposed on cytosol-localized SV40 (by mass spectrometry) should reveal if the virus is 
polyubiquitinated. Similar to SV40, cholera toxin (CT) is yet another pathogenic agent 
that transports from the ER into the cytosol to induce cytotoxicity (23). Strikingly, CT 
avoids ubiquitination to evade the degradative fate in the cytosol. This occurs because 
CTA1, the catalytic subunit of CT which undergoes ER-to-cytosol transport, harbors few 
lysine residues that are conventional acceptor sites of ubiquitination (24). Thus evasion 
of polyubiquitination may be a conserved strategy to avoid proteasomal degradation 
during ER-to-cytosol membrane penetration of pathogens. 
The last phase of productive SV40 infection requires trafficking of SV40 from the 
cytosol into the nucleus (8,9). Because SV40 does not experience significant 
disassembly in the ER, it must do so in the cytosol in order to cross the nuclear pore 
complex (NPC) and reach the nucleus. How cytosol-localized virus is disassembled is 
not entirely clear. It is possible that during entry into the cytosol from the ER, Hsp105 of 
the extraction machinery disassembles the virus, uncoating some of the VP1 
pentamers. The resulting core viral particle, harboring a residual level of VP1 
pentamers, VP2, VP3, and genome are then transported to the nucleus. Because our 
lab recently demonstrated that a dynein motor-dependent disassembly reaction is also 
required for SV40 infection, dynein might act in concert with Hsp105 to disassemble the 
cytosol-localized virus in preparation for nuclear entry (25). In such a scenario, ER 
membrane penetration of SV40 might be functionally coupled to its subsequent nuclear 
entry. 
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HPV  
Paralleling the study of ER membrane penetration of SV40, another focus of my 
thesis is to elucidate endosome membrane penetration of HPV, a critical infection step. 
During productive entry, HPV is delivered from the cell surface to the endosome (26-
29). In this compartment, the virus is targeted to the transmembrane protease g-
secretase that inserts the L2 viral protein into the membrane (30-33). This exposes a L2 
retromer-binding domain to the cytosol that recruits the retromer complex, which in turn 
directs the virus to the Golgi (33-36). Golgi membrane fragmentation during mitosis 
generates Golgi-derived vesicles (GDVs) harboring HPV that enter the nucleus due to 
nuclear membrane disassembly at the onset of mitosis (37-41). In the nucleus, HPV is 
thought to penetrate the GDV membrane to complete its membrane penetration; when 
this occurs, HPV is deposited into the nucleoplasm where DNA synthesis can occur (40, 
41). Thus, while HPV membrane insertion is initiated in the endosome, completion of 
virus membrane penetration is accomplished in the nucleus.  
When HPV reaches the endosome, it can also sort to the lysosome where the 
virus is degraded (29, 42). Thus, for productive infection to take place, HPV must avoid 
this degradative fate and instead be targeted along the endosome-Golgi axis. The 
defining event in targeting HPV from the endosome to the Golgi is g-secretase-
dependent membrane insertion of L2. How then is HPV in the endosome targeted to the 
g-secretase? My thesis work has provided some insight into this question. 
Using an unbiased biochemical strategy, our lab previously found that HPV L2 
potentially binds to a cytosolic protein called p120 catenin (31). Using standard co-IP 
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analysis, my results showed that the L2-p120 interaction begins at the cell surface and 
continues until the virus reaches the endosome. Moreover, HPV is known to bind to g-
secretase in the endosome (31). These observations raise the possibility that p120 
targets HPV from the plasma membrane to g-secretase in the endosome in order to 
support HPV infection. To test this hypothesis, I used a siRNA-mediated loss-of-function 
approach and found that p120 depletion blocked L2-HPV interaction, L2 insertion into 
the endosome membrane, and importantly, HPV infection. Because HPV L2 is not 
exposed to the cytosol at the plasma membrane, HPV’s ability to bind to p120 at the cell 
surface must be mediated by an unknown transmembrane receptor. We therefore 
postulate that the receptor-p120 complex engages HPV at the plasma membrane, 
delivering the viral particle to g-secretase in the endosome when the receptor-p120 
complex itself is recruited to g-secretase. 
Clearly the key objective to address at this point is to identify the p120-
associated receptor that binds to HPV at the cell surface. We are fully aware that this 
receptor may represent the long sought-after entry receptor of HPV. One approach to 
pinpoint this receptor is to determine host factors that bind to HPV prior to 
internalization. This could be accomplished by performing another IP-mass 
spectrometry study in which the experiment is designed so that HPV only engages cell 
surface molecules. (Our initial IP-mass spectrometry study examined host factors that 
bound to HPV post-internalization). Beyond this unbiased approach, another strategy is 
to test the function of transmembrane receptors known to bind to p120. In this context, 
p120 has been shown to associate with cadherins, which are transmembrane receptors 
well-established for their role in mediating cell-cell adhesion (43-46). In this case, p120 
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is believed to target cadherin to g-secretase, enabling g-secretase to proteolytically 
cleave cadherin and generate a cytosolic cleaved product that evokes a signaling 
response (46, 47). Interestingly, in a genome-wide RNAi screen, cadherin16 as well as 
many protocadherins were implicated as host factors that support HPV infection (35). 
Efforts are currently underway in using these two different strategies to identify the 
p120-interacting receptor that binds to HPV at the cell surface. 
We recognize that there may not be only one single receptor that binds to p120 
on the plasma membrane. In fact, different p120-binding receptors may engage HPV on 
the cell surface and promote endocytosis of the virus to the endosome. In the 
endosome, when p120 delivers the receptor to g-secretase to potentially allow g-
secretase to cleave the receptor and elicit a cellular response, HPV is concomitantly 
targeted to the g-secretase. It should be noted that while there is evidence in support of 
the presence of an entry receptor for HPV (48, 49), there is also a report suggesting that 
receptor-independent, macropinocytosis may be responsible for virus internalization 
(29). One possible explanation for these reported discrepancies is the use of different 
cell lines and pseudoviruses in the various studies.  
In a model where a receptor-p120 complex targets HPV to g-secretase in the 
endosome, an outstanding question is whether there is a conformation of HPV that is 
specifically recognized by g-secretase. Previous analyses suggested that the majority of 
L1 pentamers are released from the L2-genome complex in the endosome (50, 51). 
This is believed to be caused by the low pH and the action of cyclophilin in the 
endosome (50, 52). Conceivably, L1 pentamer release enables sufficient L2 exposure 
that allows subsequent g-secretase engagement. An experiment to test this possibility is 
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to disrupt the low pH and cyclophilin activity in the endosome, and assess if the HPV-g-
secretase interaction remains intact. Clearly, a high-resolution structure of the HPV-g-
secretase complex will provide unprecedented detail on the nature of the virus-protease 
interaction. 
After HPV is properly delivered to g-secretase by the receptor-p120 complex in 
the endosome, how does g-secretase promote membrane insertion of L2? At present, 
we do not know the precise sequence of events leading to membrane insertion of L2. 
This is complicated by the fact that g-secretase harbors 4 different subunits: PS1, NICA, 
APH1A, and PEN2 (53). Regardless of which g-secretase subunits interact with L2, and 
in which specific order this takes place, we envision two models that may explain 
membrane insertion of L2. In the first model, membrane insertion of L2 is considered 
“dynamic”. Here g-secretase acts as a “plunger”, actively inserting L2 into the lipid 
bilayer of the endosomal membrane. By contrast, in the second model, membrane 
insertion of L2 can be described as “passive”. In this case, L2 passively diffuses in and 
out of the endosome membrane due to presence of a membrane-spanning domain in 
L2 (54). g-secretase simply binds to and stabilizes L2 when it is within the plane of the 
bilayer. While we do not favor either model at this point, we presume that the dynamic 
model of L2 membrane insertion would require an energy source that enables g-
secretase to act as an insertase. This energy source might be derived from the low pH 
of the endosome, which has the capacity to induce structural rearrangements to g-
secretase essential for the insertion reaction. 
From a structural standpoint, HPV and PyV appear very similar. Both viruses 
contain a circular, double stranded DNA genome that is encased by capsid proteins with 
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T=7 icosahedral symmetry (55-58). Both virus capsids have 72 pentamers of the major 
capsid protein (27, 55, 56, 58). Minor capsid proteins associate with the major capsid 
proteins: the VP2 or VP3 minor protein of PyV associates with a single VP1 pentamer, 
while the L2 capsid protein of HPV is associated with the L1 pentamer. In addition, the 
HPV and PyV virions are similar in size, at approximately 55 and 50 nm in diameter, 
respectively. Both viruses enter into the host cell, and arrive in the endosome 
(5,7,28,29). However, from the endosome, HPV and PyV take different routes 
throughout the cell (34, 59). If both viruses are structurally similar, why then do these 
viruses takes such different routes to traffic to the nucleus where viral genome 
replication occurs?  
While there are many structural similarities between HPV and PyV, we propose 
three key differences between the virions that may account for such different routes of 
entry. First, at the amino acid sequence level, the major capsid proteins VP1 and L1 are 
quite different, with approximately 24% sequence homology. This is of significant 
importance when addressing a key protein-protein interaction: the initial binding to the 
entry receptor. GM1, the entry receptor used by SV40, targets the virus to the ER (2,3). 
During endocytosis and retrograde trafficking, transport to the Golgi is often observed; 
however, rarely are cargos trafficked to the ER (61). Interestingly, many bacterial toxins 
such as cholera toxin also bind to ganglioside receptors and are also trafficked to the 
ER (62). Perhaps the binding of cargos and pathogens to gangliosides provides a 
unique route in retrograde transport, enabling targeting from the cell surface to the ER. 
Hence attachment to a specific entry receptor may dictate the cellular destination of the 
receptor-bound ligand.  
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Second, a key difference between HPV and PyV is the presence of recruiting 
domains on the minor capsid proteins. Specifically, HPV’s L2 protein contains a binding 
motif near the cytosolically exposed C-terminus that recruits the retromer, a cytosolic 
complex that directs a cargo (e.g. HPV) from the endosome to the Golgi (35,36). 
Importantly, neither the VP2 or VP3 minor proteins of PyV contain such a domain. Thus, 
during entry, PyV does not reach the Golgi. Precisely why HPV evolved to contain a 
retromer binding domain is unknown.  
For nonenveloped DNA viruses, trafficking of the viral DNA to the nucleus from 
the cell surface poses specific challenges. Specifically, while a virus must sufficiently 
disassemble so that its genome can access the cellular replication machinery, the 
genome must also remain hidden or shielded from the host cytosolic immune factors 
that could potentially recognize the viral DNA. Therefore, a third key difference between 
HPV and PyV is their timeline for uncoating and genome exposure, which may be a 
result of capsid stability. While both virus capsids contain both intra- and inter- 
pentameric disulfide bonds, the extent and strength of these disulfide bonds may vary 
(55,56,63). As capsid disassembly is an obligate step in infection, viruses likely target to 
specific organelles to promote their uncoating. In the case of SV40, ER chaperones and 
protein disulfide isomerase (PDI) located in the ER are needed to disrupt capsid 
disulfide bonds and expose hydrophobic VP2 and VP3 (10-14). In the ER, the viral 
genome is not exposed and is likely not fully exposed until later steps in cytosolic 
trafficking as the virus nears the nucleus. Under this circumstance, the viral capsid has 
been disassembled, and the viral genome likely remains safeguarded by the minor 
capsid proteins.  
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Unlike PyV, HPV disassembly occurs in the endosome where low pH and 
cyclophilins clearly play a role in segregation of L1 from the L2-viral genome complex 
(50, 51, 52). Why cyclophilins disassemble HPV but not PyV is not known, but this may 
be due to the strength and rigidity of the different capsids. Importantly, HPV attachment 
to the primary attachment receptor at the cell surface facilitates capsid conformational 
changes proposed to partially expose the minor capsid protein L2 (64-66). Perhaps this 
conformational change starts capsid disassembly and makes further disassembly 
possible in the endosome. Because only L2 is cytosolically exposed upon interaction 
with g-secretase, the viral genome remains shielded from host cytosolic immune factors 
(31,36,41,54). In fact, throughout HPV trafficking, the viral genome remains shielded 
from the cytosol (41, 67). It is possible that, unlike PyV, after endosomal disassembly, 
the HPV viral genome is not safeguarded by L2 alone, and therefore maintains 
protection from host cytosolic immune factors by remaining safeguarded in the lumen of 
the endosome and TGN. In this circumstance, the virus is disassembled yet protected 
from the host immune response. Thus, while HPV and PyV have significant structural 
similarities from a low-resolution viewpoint, distinct variation in viral entry and trafficking 
occurs due to key differences.  
Despite variation in mechanisms of nonenveloped virus entry, important aspects 
are shared. Specifically, nonenveloped viruses must traffic to specific sites in the cell 
where at least partial viral disassembly occurs. In addition, membrane penetration must 
occur at these sites in order for productive trafficking to continue and ultimately lead to 
DNA replication. For example, similar to HPV, the non-enveloped adenovirus traffics to 
the endosome where membrane penetration occurs. However, endosomal membrane 
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penetration by the lytic protein VI of adenovirus results in complete disruption and 
penetration of the endosomal membrane, akin to the complete penetration of the ER 
membrane by SV40 (1,68). In the cytosol, the adenovirus genome remains partially 
coated and is transported to the nuclear pore complex where complete disassembly 
occurs before entry into the nucleus (69).  
Another nonenveloped DNA virus, parvovirus, undergoes endocytosis and similar 
to HPV, must penetrate the endosomal membrane. As in HPV entry, the pH of the 
endosome plays an important role in parvovirus membrane penetration, where the 
phospholipase domain in its capsid protein VP1 disrupts membrane integrity (70, 71). 
Again, similar to SV40, complete penetration of the endosomal membrane occurs. 
While pH is important for exposure of the phospholipase, the virion remains intact upon 
delivery to the cytosol and during transport to the nucleus (70,71). This would prevent 
recognition of the viral genome by host cytosolic factors. Clearly, while nonenveloped 
viruses have evolved different mechanisms of membrane penetration, two key aspects 
are generally observed for nonenveloped virus entry. First, the virus must traffic to 
specific sites in the cell where partial disassembly or conformation changes to the virus 
capsid structure occur. And second, at these specific locations, membrane penetration 
must occur. Membrane penetration is a decisive infection step and is necessary for 
delivery of the virus to the nucleus where DNA replication ensues.  
Overall summary 
In sum, my thesis study elegantly depicts how two distinct nonenveloped viruses 
exploit host machineries to support their membrane penetration process. As host 
membranes represent crucial barriers to infection, clarifying the molecular mechanism 
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of virus membrane penetration will likely have therapeutic implications. For PyV, my 
results revealed how protein quality control machineries - residing in both the ER and 
cytosol – are co-opted to promote ER membrane penetration. For HPV, my findings 
unveiled how a cytosolic adaptor of a transmembrane protease is exploited to support 
endosomal membrane penetration of HPV. I believe insights from my thesis should lay 
the foundation for novel therapeutic approaches against PyV- and HPV-induced 
diseases. As an example, because host Hsp70 chaperone machineries regulate Zika 
virus infection, new Hsp70 inhibitors have recently been developed and shown to curtail 
Zika virus-induced disease (72). Given that these Hsp70 machineries also impact PyV 
infection, the new Hsp70 inhibitors might also be effective in combating PyV diseases. 
Finally, beyond the field of virology, I anticipate that illuminating membrane penetration 
of viruses will also inform fundamental cellular membrane transport processes. 
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